1

an analyset Dift Valley for on views

1	The: Paving the way for human vaccination against Rift valley lever virus:
2	A systematic literature review of RVFV epidemiology from 1999 to 2021
3	
4	Short Title: Review of RVFV epidemiology for a human vaccination trial
5	Authors: Keli N. Gerken <sup>1</sup> , A. Desirée LaBeaud <sup>1</sup> , Henshaw Mandi <sup>2</sup> , Maïna L'Azou
6	Jackson <sup>3</sup> , J. Gabrielle Breugelmans <sup>2</sup> , Charles H. King <sup>4*</sup>
7	<sup>1</sup> Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University
8	School of Medicine, Stanford, California, USA

. . . . . . .

- 9 <sup>2</sup>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway
- <sup>10</sup> <sup>3</sup>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
- <sup>4</sup>Center for Global Health and Diseases, Department of Pathology, Case Western
- 12 Reserve University School of Medicine, Cleveland, Ohio, USA
- 13
- 14 Word count, abstract: 332
- 15 Word count, manuscript: 11402
- 16 Tables: 3 (13 supplementary)
- 17 Figures: 10 (3 supplementary)
- 18
- 19 \*Corresponding author:
- 20 Email: <a href="mailto:charlesking48@gmail.com">charlesking48@gmail.com</a> (CHK)

21

2

#### 23 Abstract

Background: Rift Valley fever virus (RVFV) is a lethal threat to humans and
livestock in many parts of Africa, Arabia, and the Indian Ocean. This systematic review's
objective was to consolidate understanding of RVFV epidemiology during 1999-2021
and highlight knowledge gaps relevant to plans for human vaccine trials.

Methodology/Principal Findings: The review is registered with PROSPERO 28 29 (CRD42020221622). Reports of RVFV infection or exposure among humans, animals, 30 and/or vectors in Africa, the Arabian Peninsula, and the Indian Ocean during the period 31 January 1999 to June 2021 were eligible for inclusion. Online databases were searched 32 for publications, and supplemental materials were recovered from official reports and 33 research colleagues. Exposures were classified into five groups: 1) acute human RVF 34 cases, 2) acute animal cases, 3) human RVFV sero-surveys, 4) animal sero-surveys, 35 and 5) insect infections. Human risk factors, circulating RVFV lineages, and surveillance 36 methods were also tabulated. In meta-analysis of risks, summary odds ratios were 37 computed using random-effects modeling. 1104 unique human or animal RVFV 38 transmission events were reported in 39 countries during 1999-2021. Outbreaks among 39 humans or animals occurred at rates of 5.8/year and 12.4/year, respectively, with 40 Mauritania, Madagascar, Kenya, South Africa, and Sudan having the most human 41 outbreak years. Men had greater odds of RVFV infection than women, and animal 42 contact, butchering, milking, and handling aborted material were significantly associated 43 with greater odds of exposure. Animal risk was linked to location, proximity to water, and exposure to other herds or wildlife. RVFV was detected in a variety of mosquito 44 vectors during interepidemic periods, confirming ongoing transmission. 45

3

46 **Conclusions/Significance:** With broad variability in surveillance, case finding, 47 survey design, and RVFV case confirmation, combined with uncertainty about populations-at-risk, there were inconsistent results from location to location. However, it 48 49 was evident that RVFV transmission is expanding its range and frequency. Gaps 50 assessment indicated the need to harmonize human and animal surveillance and 51 improve diagnostics and genotyping. Given the frequency of RVFV outbreaks, human 52 vaccination has strong potential to mitigate the impact of this now widely endemic 53 disease.

54

#### 55 Author Summary

56 Rift Valley fever virus (RVFV) is a globally important mosquito-transmitted 57 zoonosis that is also directly transmissible via aerosolization of body fluids from infected 58 animals. RVFV outbreaks cause mass mortality of young livestock and pregnancy 59 losses in both humans and animals. Severe human cases also result in hemorrhagic 60 fever, encephalitis, and death. Loss of livestock additionally threatens the livelihood of people who depend on animals for income and food. In endemic areas, initiation of 61 62 RVFV outbreaks is connected to weather events that cause excess rainfall, leading to flooding and subsequent mosquito blooms. However, the natural cycle of RVFV 63 64 transmission is complex, requiring congregation of susceptible mammalian hosts and 65 mosquito vectors in suitable environments. Several human vaccine candidates are in different stages of development, but none are yet licensed for use in human 66 67 populations. In this systematic review, we assessed the 1999-2021 frequency and distribution of RVFV outbreaks among humans, animals, and vectors to identify 68

4

potential locations and population targets for a human RVFV vaccine efficacy trial. It
focuses on current understanding of RVFV epidemiology and the identification of gaps
that pose critical barriers to controlling expansion of RVFV and implementing new
protective measures including human vaccination.

- 73
- 74

## 75 Introduction

76 Rift Valley fever virus (RVFV) remains an important emerging arboviral pathogen 77 due to its recent geographic spread and its combined disease and financial impacts on 78 vulnerable human populations [1]. Specifically, RVFV is listed as a priority pathogen by 79 the World Health Organization (WHO), the Food and Agriculture Organization of the 80 United Nations (FAO), and the U.S. Centers for Disease Control and Prevention (CDC) 81 because of its ability to cause life-threatening hemorrhagic fever and encephalitis in 82 humans [2, 3], its epidemic potential to cause severe harm to livestock [4, 5], and its 83 potential for non-vector aerosol spread during epizootics and epidemics [6, 7]. The RVF 84 virus is a member of the *Phlebovirus* genus, with three main lineages, with East African, 85 West African, and Southern African groupings.

RVFV was first identified in 1931 during an investigation into an epidemic of
fatalities among sheep on a farm in the Rift Valley Province of Kenya [8]. Since that
time, its spatial range has continued to expand from East Africa into southern Africa,
West Africa, and North Africa, and more recently outside Africa to the Arabian Peninsula
[6, 7, 9]. RVFV can infect a wide range of mammalian hosts [10] and can be carried by
many insect vectors. Floodwater *Aedes spp.* are important in maintenance during

5

interepidemic periods, whereas other Diptera serve as secondary vectors during
outbreaks in sub-tropical and temperate regions of the world [11-15]. RVFV results in
lower case fatality rates (CFR) compared to other hemorrhagic fever viruses [4], but its
outbreaks have profound compounding effects on human subsistence (from loss of
livestock) and on national economies, related to livestock export bans [16-19].

97 The critical environmental reservoir of RVFV is presently unknown. Humans 98 become infected either through the bite of an infected vector or through exposure to 99 infectious animal tissues or bodily fluids such as abortus, birthing fluids, meat, milk, or 100 blood aerosolized during slaughtering. Other than in utero transmission, there is no 101 evidence for human-human transmission of RVFV [4]. Those infected either remain 102 minimally symptomatic or develop a mild form of the disease Rift Valley fever (RVF) 103 (96% of patients), which is characterized by a febrile syndrome with sudden onset of flu-104 like fever, muscle pain, joint pain, and headache [4]. Some patients develop neck 105 stiffness, sensitivity to light, loss of appetite and vomiting and therefore RVF can be 106 mistaken for meningitis [20]. While most human cases are relatively mild, a small 107 percentage of patients will develop a much more severe form of the disease [21]. This 108 usually appears as one (or more) of three distinct syndromes: ocular (eye) disease 109 (0.5–2% of patients), meningoencephalitis (fewer than 1% of patients) or hemorrhagic 110 fever (fewer than 1% of patients) [4].

Equally important is the lethal threat to peoples' livestock. RVFV spread into naïve ecosystems is driven by infected animal movement and potentially via infected vectors [22], and can result in death of between 70-90% of young ruminants with sheep the most affected, and loss of pregnancy in nearly 100% of pregnant animals [23].

6

115 Outbreaks in humans and in animals do not occur at random. Instead they are 116 strongly linked to excess rainfall and to local flooding events [24] and the consequent 117 rise in mosquito abundance [25-32]. In addition, there is mounting evidence that 118 suggests that there is continuing low-level RVFV transmission to humans and to 119 animals between recognized epidemic periods [33-49]. Undetected infections, 120 particularly in livestock, provide an important reservoir for recurrent outbreaks, leading 121 to a continuing threat of disease in economically marginal communities and risk of 122 further geographical expansion. 123 The specific objective of this study was to consolidate the understanding of 124 recent RVF epidemiology over the recent 1999-2021 period. We sought to catalogue 125 the variability of national/regional incidence and prevalence, human risk factors and 126 populations at risk, the geospatial distribution of RVF serotypes/lineages, and the 127 present day national and regional human and animal RVF/viral hemorrhagic fever 128 surveillance systems. The systematic review also highlighted current knowledge gaps in 129 RVFV epidemiology to establish the major challenges remaining for current efforts in 130 development and testing of human vaccine. 131

#### 132 Methods

To meet our study goals, we performed a systematic review of the available published literature as well as governmental monitoring and media reports of RVF activity during the period 1999-2021. The study results are reported according to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines [50]. See S1 Table for details.

138	Inclusion/exclusion criteria. Studies included in the review were those that
139	contained reports of human, animal, and/or vector RVFV infection or exposure among
140	individuals (of any age) in countries across Africa, the Arabian Peninsula, and the Indian
141	Ocean where RVFV transmission was detected during the period January 1 <sup>st</sup> 1999 to
142	June 1 <sup>st</sup> 2021, including historical, observational, and prospective studies. Serosurveys
143	from outside this target area (Spain [51, 52], Poland [53], Korea [54], and Jordan [55])
144	were also catalogued, although not formally included in our analysis. Reports containing
145	primary human seroprevalence or incidence data, reported RVF outbreaks or cases,
146	details of RVF transmission, RVFV lineage distribution, and/or risk factors were
147	included. Reports of infections among regional livestock and wildlife during the same
148	period were also included.
149	The primary objective was to obtain population-based survey data. However,
150	georeferenced location-specific case reports were also included in spatiotemporal
151	analysis. There was no restriction according to the language of publication.
152	Excluded studies were those that reported laboratory-based studies or
153	intervention trials among experimental animals in controlled settings. Reports, reviews,
154	or opinion articles without primary data were also excluded.
155	Information sources and search strategy. To maximize detection of eligible RVFV
156	transmission studies, we searched the online databases PubMed, Web of Science,
157	African Journals Online, The Cumulative Index to Nursing and Allied Health Literature
158	(CINAHL), The Scientific Electronic Library Online (SciELO), Elsevier, ResearchGate,
159	and the Program for Monitoring Emerging Diseases (ProMED) listserv site. Animal
160	outbreak data recorded by the World Organization for Animal Health (OIE) was

161	recovered from their databases, the 2005-2021 WAHIS (https://wahis.oie.int/#/home),
162	and the older Handistatus II database (https://web.oie.int/hs2). Other sources of papers
163	and reports that were also retrieved included: i) polling colleagues involved in RVF
164	research or control for any non-indexed 'grey literature', ii) using Google Scholar
165	referrals for 'similar papers', iii) scanning of literature found in personal archives, and iv)
166	obtaining non-indexed citations found among the reference lists of the papers reviewed
167	in our study. Unpublished data from a recent survey study in Nigeria was also included
168	(Bonto Faburay and colleagues, personal communication). Details of the information
169	sources and search strategy used are available in S1 Text.
170	Selection process. Review of titles and abstracts was performed by two trained
171	reviewers who independently searched for data content meeting study requirements.
172	The studies found potentially suitable for inclusion after title-abstract review were then
173	obtained for full-text review from online or library sources. Where a single report
174	contained data on multiple individual community surveys, each of these surveys was
175	separately abstracted and given a unique ID number for inclusion in sub-group
176	comparison analyses. Studies with insufficient details of the incidence or prevalence of
177	RVFV infection were not included, and cases of duplicate publication or extended
178	analysis of previously published data were removed from the list of selected references
179	for this review. Full listings of included and excluded references are provided as
180	Supporting Information files S2 and S3 Tables.
181	Data collection process. Included papers were abstracted by two independent
182	reviewers, and their relevant features entered into a purpose-built database created with
183	Google Forms. The entries were then stored in a shared master spreadsheet in Google

9

184 Sheets. The included papers and data registry downloads were archived in electronic 185 text (pdf) or spreadsheet formats at the Department of Pediatrics, Stanford University 186 School of Medicine, and at the Center for Global Health and Diseases, Case Western 187 Reserve University. 188 Data items. For the human and animal RVFV exposures or clinical cases reported, 189 information was entered into the database based on UN geographic region 190 (https://unstats.un.org/unsd/methodology/m49), country, and the sub-national 191 administrative location details that were reported. Islands in the Indian Ocean, normally 192 classified as 'Eastern Africa' by the UN, were grouped separately for our analyses. The 193 beginning and ending month and year of the reported RVF activity or exposure study 194 were recorded, as well as information about whether the event was a recurrence of 195 transmission in a previously affected area, whether there had been flooding before the 196 event, and whether the period involved an El Nino-Southern Oscillation (ENSO) event. 197 When outbreaks spanned more than one calendar year, the year of onset was used to 198 classify the event. Study design and the eligible study population were recorded for 199 each report and whether the report involved human cases, domestic or wildlife animals, 200 or insect vectors, and the number of affected individuals by species. Where available, 201 age and gender distributions were captured for both animal and human studies, along 202 with any potential risk factors that were studied, and which were found to be significant 203 by that study. Factors evaluated for human exposure risk were age and age class, 204 gender, occupation, socio-economic status, and participation in the animal care 205 activities of feeding, herding, sheltering, or milking livestock, as well as assisting birth, 206 butchering, or skinning, and disposal of aborted material, or consumption of raw milk.

10

207 Factors evaluated for animal RVFV exposure were age and age class, sex, breed, body 208 condition, herd size, grazing strategy, and environmental conditions including proximity 209 to water, local vegetation, rainfall, and mosquito control measures. Our data extraction 210 tool was designed to capture factors related to the area the animal was raised (water 211 sources nearby, mosquito exposures, rainfall, vegetation), herd factors (grazing 212 strategy, mosquito control measures, herd size) and individual risk factors such as body 213 condition and breed. In some animal studies, the age of the animal (by dental 214 examination) and sex could be objectively assessed at the time of sampling. We 215 grouped common animal exposures and determined how many studies had assessed 216 for the risk factor and how many individual studies found statistically significant results 217 by bivariate or multivariate analyses. Not all studies separated the species of animals 218 involved within each exposure, and these have been reported as "not subdivided by 219 species." Information was recorded on the diagnostic tests used to identify acute cases 220 or exposures, and on each study's criteria used to identify suspected and confirmed 221 animal or human cases of RVF. Available information regarding local RVF surveillance 222 methods was noted, as well as any information about the RVFV lineage involved in the 223 reported cases. Where individual outbreaks were reported in more than one publication 224 or governmental bulletin, case numbers and mortality for that outbreak were taken from 225 the latest reports.

Study risk of bias assessment. We used an abridged version of the Liverpool Quality Appraisal Tool (LQAT) [56, 57] to assess study quality and risk of bias of included studies because of the tool's flexibility in accommodating different study designs and in creating potential bias assessments specific to our diverse set of studies. Scoring

11

230 involved assessment of possible subject selection bias, response bias, follow up bias, 231 bias in risk factor assessment, bias in outcome assessment, or possible bias in 232 reporting the outcome. Scoring also included whether the study's analysis involved 233 adjustment for potential confounders. The LQAT score, combined with recorded 234 information about study design and power, were used to classify reports as weak (score 235 1-5), moderate (score 6-8), or strong evidence (score 9 or 10) regarding local risk for 236 disease or exposures. Each study was assessed independently by two reviewers with 237 discrepancies resolved in consultation with a third reader. 238 Effect measures. We enumerated the cumulative number of outbreaks reported within 239 national and sub-national borders over time, and the observed incidence or period 240 prevalence by location. However, because of significant heterogeneity created by 241 reporting bias, relative risk comparisons among the multiple locations were considered 242 unreliable. Continent-wide RVF risk assessment for Africa, based on climate, weather, 243 population, and landscape factors has been recently well studied [58-63] and so was 244 not repeated here. We have, however, updated prior meta-analysis assessment [64] of 245 individual human risk factors to provide evidence regarding specific sub-groups who 246 might serve as suitable high-risk subjects for a human vaccine trial. Because the 247 chances of infection were based on post hoc determination of exposures, summary 248 odds ratios, derived by random effects statistical modeling, were used to determine the 249 strength of these associations in the meta-analysis. 250 Synthesis methods. Outbreaks and exposures were classified into five groups: 1)

acute human RVF cases, 2) acute animal cases, 3) human RVFV exposure data (based
on sero-surveys), 4) animal exposure data, and 5) insect infection data. These were

12

tabulated over time and space using frequency measures and geo-located, when

254 necessary, using Google Earth Pro software (available at

255 https://www.google.com/earth/versions/). The two decades of inclusion (1999-2010 and 256 2001-2021) were assessed jointly and then separately to determine the evolution of 257 disease, changes in detection of disease through improved diagnostics, and the effects 258 of more robust surveillance. Regional maps at the national and sub-national level were 259 then prepared using QGIS software (https://www.ggis.org/en/site/) using base maps 260 supplied by the Database of Global Administrative Areas (GADM) (version 3.4, (April 261 2018, www.gadm.org, licensed for non-commercial purposes). Surveillance systems in 262 animals, humans, and vectors were categorized either as early warning systems, 263 detection in hospital-based surveys, use of sentinel herds for surveillance, or farmer 264 reported syndromic surveillance. For meta-analysis of individual human level risk 265 factors, results from those included studies with relevant human exposure data were 266 entered into Comprehensive Meta-Analysis software, v.3 (CMA, Biostat, Englewood, 267 NJ) for calculation of pooled summary estimates of exposure effects, along with their 268 confidence intervals. Heterogeneity levels were scored using Higgins's and Thompson's I<sup>2</sup> statistic [65]. Summary estimates of intervention effects were computed using Der 269 270 Simonian and Laird random-effects modeling [66] implemented by the CMA software. 271 Summary data were presented visually by Forest plots showing the respective odds 272 ratio and 95% confidence interval ( $Cl_{95\%}$ ) for the pooled analysis. Assessment for 273 potential publication bias was carried out by visual inspection of funnel plots, and 274 statistically by calculating the Egger test. To explore heterogeneity and factors that 275 could potentially modify the summary estimates of effect, we performed subgroup

13


analyses stratified by study risk of bias, and by year of publication. For the sensitivity
analysis, each meta-analysis was retested with the exclusion of one study at a time to
assess the possibility of a disproportionate impact of any individual study on summary
estimates.

280

281 **Results** 

- 282 Studies and RVFV reports selected for inclusion
- 283 Initial screening of online publication databases yielded 7097 listings for RVF or RVFV
- during the period January 1999-June 2021 for our initial review (Fig 1). These were
- supplemented by 771 georeferenced outbreak case reports obtained from OIE
- 286 databases World Animal Health Information System (WAHIS,
- 287 <u>https://wahis.oie.int/#/home</u>) for events after 2004, and from OIE Handistatus II
- 288 (https://web.oie.int/hs2/report.asp?lang=en) for earlier 1999-2003 events. Other
- sources, including private archives, governmental reports, ProMed listings, listings from
- 290 previous systematic reviews [64, 67], and non-indexed citations (found in Google
- 291 Scholar and in bibliographies of papers under review), provided an additional 667
- reports for consideration for possible inclusion. After removal of duplicates, 1976 unique
- articles or reports were selected for full text review. After the full text review was
- 294 performed, 285 events reported in 281 publications, plus the 771 events identified in
- OIE databases and 48 from grey literature, identified a total of 1104 unique human or
- animal RVFV transmission events for inclusion in the analysis.





297

Fig 1. PRISMA systematic review flow diagram of data collection and evaluation Online searches for publications and data registers (left side flow) were supplemented by governmental outbreak reports, non-indexed citations found in local archives, and citations found within the reference lists of the papers that were reviewed (right side flow). Data from one unpublished study were also included for evaluation.

#### 304 **Report characteristics**

- 305 Of the 285 included reports selected from the published literature, 91% were in peer-
- 306 reviewed journals, 7% were in governmental reports, and 2% were in abstracts or
- 307 published correspondence. Following the regional designations of the United Nations,
- 308 43% of these papers reported RVF activity in East Africa, 13% in West Africa, 13% in
- 309 the Arabian Peninsula, 10% in North Africa, and 10% in Southern Africa. The countries
- of Kenya (n= 42 reports), Saudi Arabia (n= 32), Tanzania (n = 24), South Africa (n= 22),
- 311 Madagascar (n= 14), Sudan (n= 13), Mauritania (n= 11), and Mozambique (n= 11) were
- 312 the most frequent subjects of RVF outbreak reports and surveys. Thirty percent of
- 313 reports documented acute outbreaks (epidemics/epizootics), 61% were exposure
- 314 studies performed during interepidemic periods, and 7% were post-epidemic survey

15

studies. One hundred sixty-five (58%) were cross-sectional surveys of humans or 315 316 animals, 60 (21%) were acute case series, 35 (12%) involved prospective cohorts, and 317 4 (1%) were case-control studies. Forty-two (15%) reported on vector testing in affected 318 areas. Among published studies, 195 (68%) were non-randomized, 79 (28%) involved 319 some form of random sampling, and 11 (4%) did not clearly indicate how sampling was 320 done. In terms of study quality, the median LQAT score for published studies (where 321 higher scores indicated higher quality studies) was 6 (range = 2-11, IQR 5-7), meaning 322 the majority of studies had moderate-to-high risk of bias in assessing risk by location or 323 by sub-population. Details of all included studies, including individual risk-of-bias scores 324 are provided in S2 Table.

#### 325 Where RVFV transmission or RVF epidemics/epizootics occurred, 1999-2021

Overall, 39 countries had evidence of RVFV circulation in humans, animals, or 326 327 vectors during the 1999-2021 period, based on detection of probable or confirmed acute 328 cases, positive PCR testing, or serosurvey results (Fig 2 and S4 Table). Eighty-three 329 reports documented 124 locations in 19 countries that had 4,353 probable or confirmed 330 acute human RVF cases and 755 deaths (Fig 3), whereas 107 reports documented 331 acute RVF animal events (470 OIE confirmed cases) in 31 countries between 1999 and 332 2021 (Fig 4). The median year of reported events was 2010. Outbreaks of clinical 333 disease among humans or animals occurred at average rates of 5.8/year and 12.4/year, 334 respectively, with Mauritania, Madagascar, Kenya, South Africa, and Sudan having the 335 most human outbreak years. When month of onset was given for acute outbreaks 336 reports (epizootics or epidemics), in East Africa, 77% (27/35) of outbreaks began 337 between November and January; for southern Africa, 80% (8/10) began between March

- and June; for West Africa, 92% (12/13) began between July and October; for the
- 339 Arabian Peninsula, 93% (13/14) began between August and October; and for North
- 340 Africa, 67% (6/9) began between September and October.




Fig 2. Regional map of countries exposed to RVFV infection based on findings of
 studies included in the systematic review. Countries were categorized as to whether
 there was evidence of human, animal, or insect RVFV infection during the 1999-2021
 era.


```
347 Maps in Figs 3 and 4 show the sub-national administrative regions where acute
```

```
human and animal cases were reported during the earlier (1999-2010) or latter (2011-
```

- 349 2021) halves of our study period, or both. The countries with multiple repeated human
- outbreaks across both early and later time intervals were Kenya (n=4), Mauritania (n=5),
- 351 South Africa (n= 4) and Madagascar (n= 2). S5 Table lists dates, place names, GPS

17

- 352 locations, reported human case counts, incidence rates per 100,000, reported numbers
- 353 of deaths, and estimated case fatality risks.




354

#### 355 Fig 3. Sub-national administrative regions experiencing acute human cases of

RVF during the years 1999-2021 Locations are shaded according to whether they
 experienced outbreaks before or after 2011, or if they had outbreaks during both

- 358 periods.
- 359
- 360 In terms of epizootic activity, Fig 4 highlights the countries that experienced repeated
- acute RVF outbreaks among animals during one or both decades of the 1999-2021
- 362 period. These were Kenya (n= 4), Madagascar (n= 2), Mauritania (n= 6), Mayotte (n=
- 363 2), Mozambique (n=2), Senegal (n=3), and South Africa (n=4).



364

Fig 4. Sub-national administrative regions experiencing acute animal cases of
 RVF during the years 1999-2021 Locations are shaded according to whether they
 experienced outbreaks before or after 2011, or during both periods of time.

#### 369 Serosurveys of human and animal RVFV exposure

- 370 Of the population surveys performed during interepidemic periods to detect
- 371 evidence of prior local RVFV circulation, 50 surveyed human populations, 79 surveyed
- 372 livestock populations, and 23 tested local wild animals. Of these, eight jointly surveyed
- 373 both humans and livestock, and nine surveyed both wildlife and livestock. A summary of
- 374 available diagnostic assays used to identify anti-RVFV antibodies is presented below in
- 375 Table 1.
- 376

### Table 1. Currently used serologic assays for detection of RVFV exposure in

## 379 humans.

In-house Method	ds		
Method	Publication	Target antibody	Brief description
ELISA <sup>1</sup>	LaBeaud et al. 2008 [68]	IgG	Indirect ELISA for presence of anti-RVFV IgG antibodies at Stanford University School of Medicine using inactivated MP-12 strain for coating antigen. Validated in humans
ELISA DIVA <sup>1,2</sup>	McElroy et al. 2009 [69]	lgM or lgG	Two parallel ELISA to distinguish naturally infected from vaccination. Validated in goat and humans. Does not distinguish IgG vs IgM
ELISA <sup>1</sup>	Paweska et al. 2005 [70]	IgM and IgG	IgG sandwich and IgM capture assay that uses irradiated whole virus for antigen. Validated in humans
	Paweska et al. 2007 [71]	lgG	Antigen made using recombinant N protein. Validated in humans
ELISA <sup>1</sup>	Jansen Van Vuren and Paweska, 2009 [72]	IgM and IgG	Indirect ELISA for IgG and IgM separately. Antigen made using recombinant N protein. Validated in humans
VNT <sup>3</sup>	Winchger Schreur et al. 2017 [73]	All neutralizing antibodies	Uses a virulent RVFV that expresses enhanced green fluorescent protein. Not species specific
Optical Fiber Infrasound Sensor	Sobarzo et al. 2007 [74]	lgG	Sandwich based ELISA and antigens are immobilized on an optical fiber that makes it more sensitive. Validated in humans
Luminex DIVA <sup>2</sup>	Van der Wal et al. 2012 [75]	IgM and IgG	Bead based assay that detects RVFV Gn and N proteins
Commercially av	vailable methods		
	Manufacturer		
IFA <sup>4</sup>	EUROIMMUN	lgG	Approved for clinical testing
IFA <sup>4</sup>	EUROIMMUN	IgM	Approved for clinical testing
ELISA <sup>1</sup>	Biological Diagnostic Supplies Limited	IgM and IgG	Approved for clinical testing
ELISA <sup>1</sup>	ID-Vet	IgG	Competitive ELISA kit for the detection of anti-RVFV antibodies in serum or plasma. Multi-species that includes human validation

20

	ELISA	ID-Vet	IgM	IgM Antibody Capture ELISA for the detection of anti-nucleoprotein IgM antibodies. Validated for ruminant serum and plasma							
	1		2								
380 381 382	<sup>1</sup> ELISA: enzyme-linked immunoassay <sup>2</sup> DIVA: Differentiating Infected from Vaccinated Animals <sup>3</sup> VNT: Viral neutralization test; <sup>4</sup> IFA: immunofluorescent antibody										
383 384 385	Adapted from Petrova, et al., BMJ Glob Health 2020,doi:10.1136/bmjgh-2020-002694 [76] under Creative Commons CC BY-NC										
386											
387	livestock and wildlife anti-RVFV IgM seropositivity or IgG seroconversion were detected										
388	in areas of Namibia, Senegal, South Africa, and Kenya [47, 77-79] suggesting										
389	unsuspected one	going RVFV tra	nsmission in the	ose locations without detection of							
390	concurrent clinic	al RVF cases. /	Also of note wer	e animal studies that showed serologic							
391	evidence of RVF	V circulation ar	nong animals o	r humans within areas that had no prior							
392	evidence of RVF	V circulation. T	hese were: amo	ong animals only, in Libya [OIE], Tunisia							
393	[80], and Wester	n Sahara [81] i	n North Africa, t	out in either humans or animals in Sierra							
394	Leone [36], Côte	e d'Ivoire [82], D	)jibouti [83], Rwa	anda [84, 85], and eSwatini [OIE], i.e.,							
395	geographical are	eas in sub-Saha	aran Africa with	no previously documented transmission.							
396	Anti-RVFV antib	ody testing of h	uman patients i	n health centers in Ghana [86] and							
397	Jordan [55] did r	not detect evide	nce of local exp	osure.							
398	RVFV lineage s	tudies									
399	Twenty-si	x papers report	ed on sequence	e analysis of RVFV isolates from recent							
400	and more distant	t outbreaks in a	n attempt to ide	ntify the geographic extent of specific							
401	viral lineages in	circulation at th	e time. Although	n variants have been seen to cluster in							
402	East African West African and Southern African groupings, the results from different										

402 East African, West African, and Southern African groupings, the results from different

21

studies are heterogeneous, and nomenclature for these variants has not yet been
standardized. The included studies on strain and lineage are summarized in S6 Table.
Differences are noted depending on the segment(s) of the viral genome analyzed, the
clustering algorithm used, and the reference isolate used as a 'type specimen' for
comparison.

408 Sub-lineages of the Eastern group were found in the 1997-1998 Kenva/Tanzania 409 RVF outbreak, as well as the 2000-2001 Saudi Arabia/Yemen outbreak [87, 88]. These 410 were most similar to the RVFV isolates from humans, animals and insects the Kenya 411 2006-2007 epidemic (when variants termed Kenya-1, Kenya-2, and Tanzania-1 co-412 circulated) [87, 89]. Later 2008-2009 isolates from outbreaks in Comoros [90], Mayotte, 413 and Madagascar [91, 92] were also from the Eastern group. Although Eastern African 414 group isolates were recovered from Mauritania in 2010 [93] and Senegal in 2013 [94] in 415 West Africa, outbreaks in these countries in other years have identified a separate West 416 African lineage grouping of RVFV isolates [95, 96]. Grobbelaar and colleagues [97] 417 have used the sequence from the viral Gn surface peptide to compare 198 isolates 418 recovered between 1944-2010 from across Africa and the Arabian Peninsula, and have 419 defined 15 different lineages, which they have labeled A through O. South African 420 isolates in 2008 were grouped in the C lineage, related to the Kenya-1 lineage. 421 However, during 2009-2011, South African isolates were predominantly found in a new, 422 separate lineage H [98], while one isolate in Northern Cape Province was from lineage 423 K. Lineage K was later identified in a small South African outbreak in 2018 [99], and in 424 an RVFV-infected Chinese expatriate working in Angola in 2016 [100].

22

### 425 **Table 2. Rift Valley fever virus lineage determinations for isolates recovered in**

426 recent epidemics, based on cluster analysis of gene sequences for the viral Gn

427 surface protein. (Based on Grobbelaar, et al. 2011 [97])

428

Grouping	Grobbelaar System	Year	Country	Species	Lineage Notes	Reference
East African	lineage C	2000-01	Saudi Arabia, Yemen	Human	Very similar to 1997-98 isolates/variant s Kenya-1, Kenya-2, and Tanzania-1	[87, 88]
	lineage C	2006-07	Kenya	Humans, Livestock, Vectors		[87, 89]
	N/A	2007	Comoros	Humans	Similar to Kenya 2006-7	[90]
	lineage C		Madagascar			[91, 92]
West African			Mauritania, Senegal, Niger		Related to Kenya-1 lineage	[95, 96]
Southern African	lineage C	2008-09	South Africa			[97]
	lineage H	2009-11	South Africa			[101]
	lineage K	2009-11	South Africa			[101]
	lineage K	2018	South Africa			[99]
	lineage K	2016	Angola/China			[100]

429

#### 430 Human outbreak characteristics

During human outbreaks, surveillance and reporting efforts varied greatly from location to location. We observed that among human outbreak reports, the calculated incidence rates of probable or confirmed human RVFV infections among local or regional residents varied between 0.01 and 91 per 100,000 population, with a median value of 2.5. Case fatality risks for these probable or confirmed cases varied from zero to 65% (median = 14.3%) in locations where more than one case was reported (n= 107 locations from 41 publications, see S5 Table).

23

438	The cumulative human exposure to RVFV infection is also heterogeneous across
439	locations. In endemic areas, this cumulative exposure is usually estimated based on the
440	population prevalence of human anti-RVFV IgG seropositivity. Among the 25 well-
441	designed population-based serosurveys (scored as having low risk-of-bias) among our
442	included reports (n= 44), IgG seroprevalence during interepidemic periods ranged from
443	(0.15%) in Madagascar in 2014-2015 [40] to 22% in eastern Kenya in early 2006 [102]
444	and again in 2013-2014 [103], with an overall median intra-epidemic value of 5.2% (IQR
445	1.8% - 13%) seropositivity across all 25 surveys.

- 446
- 447





Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions
 across Africa, the Indian Ocean, and the Arabian Peninsula

451

24

452	Acute human RVF outbreaks were reported across Africa, the Arabian Peninsula, and
453	the Indian Ocean from 2000-2021 (Fig 5). The highest number of reported human RVF
454	events occurred in 2006-7, starting in East Africa, moving to Sudan (North Africa) and
455	then to the islands in the Indian Ocean during 2007-2008, as part of an evolving
456	epidemic and epizootic of the East African RVFV lineage. In East Africa, new RVFV
457	outbreaks have recurred annually since 2016, whereas no new human cases have been
458	reported in the Arabian Peninsula since 2001. RVF flared in southern Africa in multiple
459	episodes between 2008 and 2011 and West African countries Mauritania and/or
460	Senegal have reported cases across multiple years, 2003. 2010, 2012-3, 2015-6, and
461	again in 2020.

462



25

# 464 Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions 465 across Africa, the Indian Ocean, and the Arabian Peninsula 466

467	A larger number of acute animal RVF events (N = 273), compared to human events (N
468	= 132), was reported during the 1999-2021 period studied. The reported animal events
469	in southern Africa (N= 31) and in the Indian Ocean islands (N= 19) were concentrated
470	during the 2008-2011 period (Figs. 5 and 6). By contrast, animal events in West Africa
471	and East Africa were reported during most years of the targeted time interval
472	(cumulative N= 80 and N=118, respectively), with the highest yearly tally being 41
473	reported events in 2018 (Fig 6). No animal event was reported in the Arabian Peninsula
474	after 2010, while only a low number of events were reported in Central and North
475	African countries between 2002-2019 (cumulative N= 8 and N= 9, respectively; Fig. 6).
476	Of 28 papers that reported both human and livestock data, 17 contained
477	information on concurrent co-local RVF epidemic and epizootic activity. These reports
478	documented combined human/animal RVFV transmission events in Saudi Arabia [104,
479	105] and Yemen [106] in 2000-2001; in Egypt [107] and Mauritania [108] in 2003; in
480	Kenya [5, 89] and Tanzania [89, 109] in 2006-2007; in Mauritania in 2010 [93, 110] and
481	again in 2012 [111]; in Senegal in 2013-2014 [94]; in Niger [96] and in Uganda [112] in
482	2016; and in Kenya [113], Mayotte [114], and South Africa [115] in 2018.
483	Evidence of vector presence and competence for interepidemic RVFV
484	transmission. In S7 Table we summarize 31 published studies from 1999-2021 that
485	tested insect vector species for RVFV infection potential. Our systematic review
486	identified 21 locations with RVFV-positive vectors, including mosquitos from Aedes,
487	Culex, Anopheles, and Mansonia spp. and from Hyalomma spp. ticks (Fig. 2). Notably,

26

488 in 6 out of 10 trapping surveys performed during interepidemic years in endemic zones. 489 live RVFV or RVFV RNA was detected in captured vector mosquitoes or ticks [116-121]. 490 As the lifespan of mosquito vectors is relatively short, the presence of RVFV viral RNA 491 in these vectors likely represents sustained circulation in each of the given locations. 492 Human risk of RVFV-related disease. Among our included studies from the 493 systematic review, 84 reports assessed human risk factors for RVFV exposure. The 494 factors most commonly assessed were occupation (33 papers), gender (30), age (89), 495 contact with animals (38), travel (15), as well as proxies for mosquito exposure such as 496 work or residence in proximity to water sources (12), and personal behaviors related to 497 mosquito avoidance (29). 498 Quantitative assessment of the role of gender involved estimation of chances for 499 RVFV exposure by men and women in endemic settings. There were 31 studies that 500 reported RVFV exposure (cases or anti RVFV seropositivity) according to gender (Fig 7). There was moderate heterogeneity among these studies ( $I^2 = 39\%$ ), and random 501 502 effects modeling estimation yielded a summary pooled OR estimate of 1.41 (Cl<sub>95%</sub> 1.24, 503 1.60, p < 0.001) for males vs. females in their exposure rates (Fig 7). This value, based 504 on studies from 1999-2021, remained very similar to that calculated by Nicholas and 505 colleagues [64] (OR = 1.36) in their meta-analysis of studies from 1984-2011.

27

## Male: Female Odds Ratio for Human RVFV Infection

Study name	Period	Time Interval	Statistics for each study				Odds ratio and 95%Cl				
			Odds ratio	Lower	Upper limit	p-Value					
Sanderson (2020)	IEP	1985-2019	1.864	1.073	3.236	0.027	1			∎	1 1
Marrama (2005)	IEP	1999	1.130	0.717	1.778	0.599			_   <b>-</b>		
Swai (2009)	IEP	2004	3.675	0.445	30.373	0.227					<u>→</u>
Porrut (2010)	IEP	2005-2008	1.768	1.260	2.481	0.001					1 1
LaBeaud (2008)	IEP	2006	2.428	1.130	5.219	0.023					→ I
Muiruri (2015)	IEP	2006	2.643	1.252	5.578	0.011					+
Anyangu (2010)	Outbreak	2008-2007	1.424	1.038	1.958	0.030					1 1
Aradib (2013)	Outbreak	2007	1.378	0.724	2.623	0.329					1 1
Hassanian (2010)	Outbreak	2007	2.760	1.177	6.470	0.020					<u>+</u> − ∣
Ochieng (2015)	Postepidemic	2007	1.283	0.751	2.192	0.362				┿╋┿	
Al-Azragi (2012)	IEP	2007-2008	0.949	0.647	1.390	0.787				<b>-</b>	1 1
Heinrich (2012)	IEP	2007-2008	1.000	0.608	1.645	1.000			<u> </u>	·	
LaBeaud (2011)	IEP	2009	2.324	1.173	4.603	0.016					-
Byomi (2015)	IEP	2009-2010	1.379	0.717	2.650	0.335					1 1
Grossi-Soyster (2017)	IEP	2009-2011	0.808	0.436	1,499	0.499				╺┿╾╸╴	1 1
Tigoi (2015)	IEP	2009-2012	0.720	0.417	1.242	0.238				<b>→</b>	1 1
Andayi (2014)	IEP	2010-2011	1,170	0.483	2.833	0.727					1 1
Cook (2017)	IEP	2010-2012	0.452	0.147	1.384	0.164				<b>→</b> →	1 1
Nakoune (2016)	IEP	2010-2012	1.866	0.704	4.945	0.210			-		
LaBeaud (2015)	IEP	2011	1.463	1.048	2.043	0.026					1 1
Lemout (2013)	IEP	2011	1.453	0.822	2.568	0.198			- I -	┿╼┿	1 1
Gray (2015)	IEP	2012	0.985	0.531	1.828	0.962				<b>•</b>	1 1
Sumnaye (2015)	IEP	2012	1.260	0.767	2.071	0.361				┿╋╾┽	1 1
Gudo (2016)	Outbreak	2013	1.531	0.605	3.875	0.369					1 1
Bett (2019)	IEP	2013-2014	1.520	1.008	2.291	0.048				┝━┳┿	1 1
Ahmed (2018)	IEP	2014	1,432	0.719	2.851	0.307			<u> </u>		1 1
Tigoi (2020)	IEP	2014-2015	1.670	1,108	2.387	0.005					1 1
Nyakarahuka (2018)	Outbreak	2016	2.705	1.511	4.843	0.001					-
Poole	d OR (rand	om effects)	1,410	1.240	1.604	0.000				•	1 1
					0.1	0.2	0.5	1 2	5 10		
							0.1	0.2	0.5		5 10
								Fen	nale	Male	Э

506

#### 507 Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in 508 at-risk populations

509


510 Greater human risk associated with animal contact. Eleven well-structured 511 human surveys (having moderate to low risk of bias, i.e., LQAT scores ≥ 6) compared 512 rates of RVFV exposure among local residents according to the extent of their daily 513 contact with animals, particularly ruminant livestock. Heterogeneity was high among 514 these studies ( $I^2 = 68\%$ ). However, random effects meta-analysis, summarized in the 515 Forest plot in Fig 8, yielded a summary OR estimate signifying a 46% increase in the 516 odds of RVFV exposure among people with regular animal exposure (random effects 517 model pooled OR = 1.46,  $Cl_{95\%}$  = 1.09, 1.94, p= 0.01) in at risk populations. In separate

28

518	task analyses, S1-S3 Figures show Forest plots for summary estimates of associations
519	between butchering, sheltering, and milking livestock activities and risk of RVFV

- 520 exposure among at-risk populations. The estimates were: for butchering, OR = 3.7
- 521 ( $CI_{95\%} = 2.5, 5.4, p < 0.001, I^2 = 75\%$ ); for sheltering, OR = 3.4 ( $CI_{95\%} = 2.1, 5.4, p < 0.001$ )
- 522 0.001,  $l^2 = 57\%$ ); and for milking, OR = 5.0 (Cl<sub>95%</sub> = 2.8, 8.8, p < 0.001,  $l^2 = 77\%$ ),
- 523 indicating significantly higher risk with these exposures. Among these pooled studies,
- 524 there was no evidence of publication bias (by funnel plot or by Eggar's statistic). There
- 525 were no yearly trends in exposure effects, nor did sensitivity analysis indicate evidence
- 526 of any single dominant study for each exposure-related outcome.

## Odds Ratio of RVFV Infection When Exposed to Animals



Less likely More likely

- 528 Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure
- 529 in at-risk populations.

# Odds Ratio of RVFV Infection When Handling Abortus

Study name	Period	Time Interval	Statistics for each study						Odds r	atio and	95%CI		
			Odds ratio	Lower limit	Upper limit	p-Value							
LaBeaud (2008)	EP	2006	2.780	1.029	7.512	0.044				- I	┈╴	-+	-
Muiruri (2015)	EP	2006	5.320	2.491	11.361	0.000						— <b>—</b> ——————————————————————————————————	>
Anyangu (2010)	Outbreak	2006-2007	3.830	1.619	9.062	0.002					-	∎⊢	_
Al-Azraqi (2012)	EP	2008	11.583	6.950	19.306	0.000						_	$\rightarrow$
Archer (2011)	Outbreak	2008	0.715	0.114	4.477	0.720	—				_	_	
LaBeaud (2011)	EP	2009	3.490	1.522	8.002	0.003					<b>—</b>	∎┿	-
LaBeaud (2015)	EP	2011	5.310	3.389	8.319	0.000							-
Lemout (2013)	EP	2011	11.120	1.101	112.357	0.041				I-	_	$-\top$	$\rightarrow$
Memish (2015)	EP	2012	3.200	1.168	8.764	0.024				_   <b>_</b>		⊢+−	
Sumaye (2015)	EP	2012	2.020	1.151	3.547	0.014				—	-	-	
Msimang (2019)	EP	2015-2016	1.724	0.965	3.079	0.066				-			
Pooled OR (random effects)		3.646	2.321	5.728	0.000								
							0.1	0.2	0.5	1	2	5	10

Less likely More likely

530

#### 531

#### 532 Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on 533 odds of human RVFV exposure in at-risk populations 534

535 Thirty-nine included studies assessed human RVFV-infection risk factors related

536 to different animal exposures and 17 of those studies linked animal exposures to acute

537 human RVFV infections (S8 Table). In meta-analyses performed according to specific

538 animal contact tasks, handling aborted material during an RVF outbreak had the

539 greatest pooled odds ratio of human infection (random effects model pooled OR = 3.65,

 $Cl_{95\%} = 2.32, 5.73, p < 0.001, l^2 = 73\%$ ). 540

Our survey also provided individual reports of an additional 21 significant animal 541

542 contact risk factors that had not been commonly assessed. In a study in Tanzania

- 543 during the 2006-2007 East Africa outbreak, 40% of 115 RVFV cases reported having
- 544 contact with animal products including meat and milk from sick animals, compared to
- 545 just 28% of the cases reporting having slaughtered an animal [122]. Specifically,

30

consumption of meat from sick animals was associated with a nearly four-fold increased
risk of RVF-associated death during the 2006-7 outbreak in Kenya [68].

548 Occupational and socioeconomic factors associated with RVFV exposure. 549 Our systematic review identified seven studies overall that found statistically significant 550 risks related to socioeconomic factors such as education level, ethnicity, and household 551 size. Briefly, the less wealthy and less educated were overrepresented among RVFV 552 exposed people (S9 Table).

553 Forty-five of the 506 papers assessed occupation as a human risk factor and 14 554 references found occupation to be a statistically significant factor (S10 Table). For 555 clarification, those who were classified as 'herders' may not necessarily live a pastoralist 556 lifestyle, so they have been given separate status. We found three studies that reported 557 high seroprevalence among "housewives", which might be explained by their frequent 558 handling of raw meat and animal products for cooking.

559 Risk Factors for RVF severity. Out of the 135 included papers assessing 560 human RVFV exposure and disease, 12 presented data on human risk factors 561 associated with more severe RVF disease presentation (S8 Table). Persons with animal 562 contact were usually more likely to have had severe disease, [21, 123, 124]. In 563 outbreaks in Kenya [123, 124], specific animal contact activities such as handling or 564 consuming products from obviously sick animals (OR for more severe disease = 2.53, 565  $CI_{95\%} = 1.78, 3.61$ , population attributable risk percentage [PAR%] = 19%) and touching 566 an aborted animal fetus (OR = 3.83, 95% Cl<sub>95%</sub> = 1.68, 9.07, PAR% = 14) were strongly linked to risk of severe rather than mild human RVF disease. Older age and death of a 567 568 family member were also linked to more severe human disease [123]. In Sudan, males

31

569	aged 15-29 years were overrepresented among patients who presented with severe
570	disease, as compared to females of the same age [125]. Environmental factors, such as
571	excess rainfall and muddy soil linked to emergence of mosquito blooms have also been
572	linked to severe human disease in both Sudan and Kenya [126, 127].
573	Severity of human RVF was associated with the presence of concomitant co-
574	infections. A fatal outcome in a travel related case was attributed to the presence of
575	concurrent hepatitis A virus infection [45]. Additionally, a study in South Africa during the
576	2010 RVFV outbreak indicated that existing HIV-positive infection status was associated
577	with risk of the encephalitic form of RVF disease [128], a finding similar to experience
578	among HIV-infected patients in Tanzania in 2007, where all patients with HIV-positive
579	status developed encephalitis, and of whom 75% died [122].
580	Four studies performed in three countries (Kenya, Sudan, Saudi Arabia),
581	examined the risk factors linked to death from RVF. In Kenya in 2007, consuming and
582	handling products from sick animals and village and district location were linked to risk
583	of death (OR = 3.67, CI <sub>95%</sub> = 1.07, 12.64, PAR% = 47%) [124, 129]. In Saudi Arabia, a
584	retrospective analysis of the 2000-2001 outbreak showed that specific clinical signs
585	were independently linked to death. These included jaundice, bleeding, and neurologic
586	symptoms (P < $0.0002$ ) [130]. One study demonstrated an increased level of RVFV
587	replication in fatal RVFV [131].
588	Risk factors for animal RVFV outbreaks. Because human risk of RVFV

exposure is closely associated with the local presence of infected livestock, we

590 reviewed factors related to animals' risk of RVFV infection.

32

591 Herd Immunity Levels. Our systematic review included results from 174 animal 592 studies, in which 144 tested domestic livestock and 26 tested wild animals for RVFV 593 exposure and/or acute infection. Of all livestock studies included, 32 were conducted 594 during an active epizootic, 10 were conducted just after an outbreak in the post-595 epidemic phase, and 97 were conducted during interepidemic years. For wildlife 596 surveys, 5 were carried out during an active epizootic, 5 were done in the post-epidemic 597 phase, and 14 were performed during interepidemic periods. Of all animal risk factors, 598 sex and age were the most studied, and older animals and those that had lived through 599 outbreaks were more likely to have been exposed. A summary of livestock risk factors is 600 presented in S11 Table.

601 Herd Level Risks. For herd level risks, the observed effects of herd size has 602 varied across studies. A 2013-2014 study in a high risk area of Kenya showed that 603 medium sized herds of 50-100 animals had a significantly higher seroprevalence 604 compared to small herds (< 50 animal) or very large herds (>100 animals) [132], though 605 this did not account for the differences in animal rearing strategies dependent on herd 606 size. The statistical significance of herd size was lost when village was accounted for as 607 a random effect [74]. In Tunisia, the first assessment of serology in camels in 2017-608 2018 showed that camels living in smaller herds intended for meat production had a 609 higher seroprevalence than those used for military purposes or tourism. Additionally, 610 this study found that camels that had contact with ruminants had significantly higher 611 rates of RVFV exposure [80].

612 The differing levels of RVFV susceptibility across livestock species (S11 table) 613 further complicates the herd immunity threshold related to animal-to-human RVFV

33

spillover. Additionally, livestock had variable contact with other livestock from
neighboring herds and regions. An extensive social contact analysis from the 20082009 Madagascar outbreak showed that bartering practices, in which cattle can have
multiple contacts within a village, was a significant seroconversion risk factor [133].
Such bartering practice can support for inter-village RVFV circulation, whereas formal
trade networks or cross-border smuggling were more likely to be responsible for transnational spread [134, 135].

Individual Animal Risks. For individual-level animal risk, studies examining cattle
 had the most significant findings. Abortion was the most recognized clinical sign
 associated with RVFV infection and recent abortion was significantly associated with
 RVFV exposure [136]. This experience was the first to identify the 2018 RVFV
 outbreaks in Kenya when farmer-reported surveillance was implemented [126]. None of
 the included studies found an association between underlying animal body condition
 and RVF risk.

Wild animals' role in RVFV transmission. RVFV has been found in a variety of
wild mammals [48]. Wild ruminants, especially buffalo, have been found to have
significant herd seroprevalence during inter-epidemic period in endemic areas [46, 137,
138]. For species-specific risk factors, interspecific network centrality, home range and
reproductive life-history traits were associated with RVFV occurrence. S12 Table
summarizes the wild animal seropositivity and acute infections identified in our literature
review.

Animal Vaccination. Among the included papers in this review, we identified 17
 studies in six countries that included vaccinated animals. Countries that had vaccinated

34

637 cattle, sheep, or goats for RVFV were Kenya, Tanzania, South Africa, Egypt, and Saudi 638 Arabia [5, 139-143]. In Egypt, between 2013 and 2015, seroprevalence of anti-RVFV 639 was 14.9% among immunized cattle, compared to 7.9% among unimmunized cattle 640 [144]. Although livestock are required to be vaccinated before they are exported to 641 Saudi Arabia, a study at a livestock guarantine facility in Dibouti found an anti-RVFV 642 IgM-positive seroprevalence of 1.2% in sheep and goats (small ruminants grouped as 643 'shoats') and 0.3% in cattle [139, 145]. A 2009 study in Mecca, Saudi Arabia found 644 55.8% anti-RVFV IgG in ostensibly vaccinated sheep, but still found a 2.6% rate of IgM 645 positivity, indicating possible ongoing circulation (despite herd vaccine status) or recent 646 vaccination[146].

Additional considerations for RVF risks. The range of RVFV is expanding, and it appears to travel well [39, 147, 148]. In endemic countries, internal travel to or from outbreak epicenters is typically included in suspect case definitions. A recent review by Grossi-Soyster and LaBeaud [149] has highlighted the risk of RVFV transmission to travelers, and although most travelers will not have direct contact with livestock, their mosquito exposure behavior needs to be assessed.

Reported surveillance methods in animal, humans or vectors are summarized
in S13 Table. Our review revealed 52 papers specifically reporting on RVFV
surveillance. Their methods are not uniformly implemented, but include: i) leveraged
RVFV testing of samples taken during surveillance for other diseases such as malaria,
dengue, HIV, and Lassa fever [38, 150-152]; ii) the use of sentinel livestock herds in
high-risk areas; iii) increased case surveillance based on monitoring of weather-related
early warning signs; and iv) international collaborations with neighboring regions to

35

660 conduct surveillance. These surveillance systems do not necessarily operate in parallel,

but instead may overlap and may only be implemented at times of perceived increased


662 risk.

663 Fig 10 depicts the different types of early warning and surveillance systems and

their relative certainty. S13 table further summarizes available information from open-

665 source platforms on the early warning and surveillance systems used for RVFV

transmission during 1999-2021.



667

time

668 **Fig 10** Progressive scale of surveillance that can used to indicate an impending RVFV disease 669 outbreak

670 Republished with permission of The National Academies Press, from Under the Weather:

671 Climate, Ecosystems, and Infectious Disease (2001), Chapter 7: Towards the Development of

672 Disease Early Warning Systems. P. 87; permission conveyed through Copyright Clearance

- 673 Center, Inc. under license ID **#1142222**
- 674
- 675

**RVFV Diagnostics.** When implementing surveillance for detecting RVFV

transmission, one major constraint is the limited availability of accurate diagnostics in

677 places where RVF disease occurs. For both human and animals, reliance on a clinical

36

678	presentation to prioritize	<b>RVFV</b> testing is	complicated b	by the significant clinical	
-----	----------------------------	------------------------	---------------	-----------------------------	--

- 679 diagnostic overlap with other febrile infection syndromes.
- 680 Although detection of circulating RVFV RNA by RT-PCR can be a definitive
- diagnosis of active infection, because the human and livestock viremic period is typically
- only 4-6 days (up to 14 days if hemorrhagic human disease), serologic testing is more
- 683 extensively used to investigate the epidemiology of recent and past infection. We
- 684 extracted data from 207 included review reports on the type of assays recently
- 685 employed for diagnosis of acute RVF. No studies tested livestock and wild animals
- 686 together for acute infection. The assays used to detect acute RVFV infections are
- 687 summarized in Table 3.
- 688

#### **Table 3: Summary of acute diagnostic assays employed in included studies, by**

690 species

Numbe	er of Ind	cluded St	udies th	at Used th	ne Follov	ving Me	ethods fo	or Detectio	on of Ac	ute RVFV	' Infecti	on
Species	IgM	IgM, direct <sup>1</sup>	lgM, PCR	IgM, PCR, direct <sup>1</sup>	lgM, PCR lgG SC <sup>2</sup>	IgM, IgG SC <sup>2</sup>	PCR IgG SC <sup>2</sup>	Direct <sup>1</sup> only	PCR only	PCR, direct <sup>1</sup>	IgG SC <sup>2</sup> only	Total
Livestock	26	0	4	0	1	3	2	0	5	0	3	44
Humans	21	2	23	4	2	0	0	2	9	1	0	64
Humans, livestock	1	1	5	3	1	0	0	0	1	0	0	12
Humans, livestock, wildlife	0	0	0	1	0	0	0	0	0	0	0	2
Wildlife	0	0	1	0	0	0	0	1	0	1	1	4
Method Total	48	3	33	8	4	3		3	15	2	4	

<sup>1</sup>Direct: Direct detection methods include immunofluorescence assay, cell culture (virus isolation), electron microscopy, and immunohistochemistry

37

<sup>6</sup>93 <sup>2</sup>SC: IgG Seroconversion of IgG (positive IgG during the study period AND a previously
 <sup>6</sup>94 documented negative status from the same individual)

- 695
- 696 697

### 698 **DISCUSSION**

699 During RVF epidemics, assessment of incidence, prevalence, and associated 700 risk factors for infection are often based on case series of suspected patients, rather 701 than well-designed, population-based surveys that enumerate laboratory-confirmed 702 cases vs. non-cases. Epidemic and epizootic outbreak surveys are further hampered by 703 limited access to the affected rural communities, which are often experiencing severe 704 flooding caused by excessive rainfall, and very limited access to diagnostic testing. In 705 addition, survey incidence/prevalence calculations may be imprecise because of lack of 706 accurate census information. As a result of these factors and the irregular frequency of 707 disease outbreaks, the epidemiology of RVFV transmission and the risk factors for 708 RVFV-related human disease are not well defined. In some endemic areas, post-709 epidemic serosurveys have shown high community exposure to RVFV [68, 103, 151-710 156], even though symptomatic RVF had been only rarely reported by local health care 711 services. Based on our consolidated picture of recent RVFV epidemiology and the 712 knowledge gaps we have identified, future operational research and clinical trial design 713 should consider the factors discussed below, with the understanding that currently 714 available data have some significant limitations in accurately defining human risk for 715 RVF.

Our review indicated that during the last two decades, new patterns of RVF epidemiology have emerged. The virus continues to expand its range across Africa countries and into new regions within endemic countries [58, 157]. It should be noted

38

719 that among studies that were technically excluded from our review, there were several 720 completely negative serosurveys of animals performed in Spain [51], the Canary Islands 721 [52], Mauritius [158], Zanzibar [159], South Korea [54], and Poland [53]. Expansion of 722 RVFV transmission has been aided by livestock movement [34, 160-163] and the 723 increasing frequency of extreme weather events involving heavy rainfall and flooding [59]. The discovery of vertical transmission within insect vector species other than 724 725 floodwater Aedes spp. mosquitoes [164] indicates the existence of multiple pathways for 726 local RVFV persistence in different ecosystems during time periods that are in between 727 recognized outbreaks. An additional non-vector route of RVFV transmission to humans, 728 i.e., maternal-fetal transmission, has also been identified recently [165-167], and it has 729 been established that RVFV can be an abortifacient in humans [168]. Thus, treating 730 RVF as a concern only during large scale outbreaks in known hotspots fails to capture 731 the full burden of disease and its underlying transmission, and fails to detect new areas 732 of emergence.

The limited understanding of transmission persistence during interepidemic periods is a major gap affecting our ability to control continued expansion of RVFV, both within and between countries. Prospective studies during interepidemic periods are needed to provide a deeper understanding of how RVFV survives then subsequently thrives in an endemic area. Study findings could then suggest how mitigation efforts, such as vaccination of high-risk humans, can be implemented even before existing surveillance systems detect an outbreak.

Gap 1: Defining the likely interval between significant RVF outbreaks is
 challenging, because without active case finding, passive detection is an imperfect

39

742 trailing indicator of transmission, as it requires a large enough case number of RVF 743 clinical syndromes (e.g., abortions in livestock) to identify events. Over the last two 744 decades, increased availability and sensitivity of RVFV diagnostic assays, including 745 genotyping, have contributed to increased recognition of viral transmission. However, 746 without baseline interepidemic surveys in both high and low risk areas it is not possible to determine whether RVF outbreak waves are due to persistence or to re-introduction 747 748 of RVFV transmission. As the outbreak intervals for RVFV remain undefined, the lack of 749 studies during interepidemic periods limit our ability to understand viral maintenance 750 and make it difficult to qualify endemicity in support of mitigation efforts such as 751 vaccination. More useful data would include concomitant active surveillance of vectors, 752 livestock, and humans, and information on rainfall, temperature, mosquito larval 753 sources, and the frequency of risk-related human behaviors. Because RVF livestock 754 outbreaks are up to five times more likely to occur where outbreaks have previously 755 occurred, and human outbreaks are more likely to occur in the same locations as 756 livestock outbreaks [5, 169], areas with prior RVFV transmission shown in Figs. 3 and 4 757 would be best locations to characterize interepidemic transmission. 758 Kenya, South Africa, Madagascar, and Mauritania have had recurrent human 759 and domestic animal RVF outbreaks in the last two decades and are thus most likely to 760 experience additional outbreaks in the near future. Notably, areas with recurrent

outbreaks tend to have more robust surveillance which may account for the higher

762 frequency of RVF detection in those locations (i.e., ascertainment bias). Based on

findings identified in this systematic review, RVF can be more likely in a given location,

compared to a similar nearby location due to many factors, including the total number of

40

susceptible hosts (influenced by herd immunity), the presence of wildlife reservoirs
[170], the water retention properties of the soil and rainfall patterns [62], local cultural
practices that may increase (consumption of blood) or decrease risk (refusing to eat
meat from dead animals) [171], and mitigation efforts that persist between outbreaks.
As these factors can be confounded, an in-depth understanding of RVFV epidemiology
is needed to design investigations so that resources for operational research can be
maximized.

772 Gap 2: The unpredictability of livestock herd immunity Current prevention 773 and readiness efforts for RVFV outbreaks rely mostly on early warning prediction and a 774 rapid livestock vaccination response, both of which occur with variable reliability. 775 Recovery from infection and vaccination with live-attenuated vaccines are thought to 776 result in lifelong neutralizing antibodies in livestock [172] and indeed, if enough livestock 777 could be vaccinated for RVFV, then human spillover would be unlikely [173]. However, 778 livestock within and between herds have a rapid turnover rate as animals are 779 slaughtered and sold, or arrive naïve into the herd from new births or purchases. 780 Additionally, livestock in RVFV endemic countries often live in close proximity to wild 781 ruminant species that also acquire many naïve animals each breeding season. The 782 logistics and current intermittent nature of domestic livestock vaccination campaigns, in 783 the face of unknown baseline herd immunity levels, makes full reliance on reactive 784 livestock vaccination a risky approach to RVFV public health control. 785 Most livestock animal studies have focused on cattle, sheep, and goat

seroprevalence. Although some surveys have used power analysis to determine how
many animals to sample from each species, many surveys have still opted for

41

788 convenience sampling, focusing either on sheep and goats, which are easier to handle, 789 or on just cattle alone. The interpretation of such livestock prevalence surveys should 790 be viewed with caution. Animal age is also likely to influence the results-- cattle and 791 dairy animals tend to live longer than sheep or goats, so it can appear that their 792 cumulative burden of exposure is higher. However, evidence of infection among 793 younger animals does provide evidence for recent RVFV transmission activity, and 794 increased seroprevalence between years can indicate an unrecognized outbreak. When 795 multiple species are surveyed, rates should be calculated based on animal-years at risk 796 and better attempts should be made to age animals based on their dentition. Factors 797 that confound RVFV exposure risk should be captured, such as the wealth and 798 knowledge of the farmer [113], area livestock density, and location-specific climate 799 factors. We suggest factors such as nearby temporary and permanent water bodies. 800 land use, mobility at peak mosquito biting times, housing conditions, and rearing 801 strategy be combined with climate data to better discern spatial and temporal high-risk 802 periods for livestock. This will be important in defining optimal locations for human 803 vaccination trials.

As the previous systematic review by Clark, et al. [67] has highlighted, and as we found in our review, there are few studies that assess both human and animals from the same site at the same time. The high-risk periods for livestock and humans may not necessarily overlap, as livestock infections are undoubtedly driven by rainfall and mosquito blooms, but human outbreaks can also expand with increased slaughtering of sick animals and the increased presence of secondary mosquito vectors.

42

810 It is understood that livestock viral amplification is an important predecessor of 811 human outbreaks. The greater number of acute animal events (N=273), compared to 812 human events (N=132) identified in this review could be due to our increasing ability to 813 detect smaller animal outbreaks or could represent our inability to reliably detect acute 814 human cases associated with smaller animal outbreaks [174, 175]. After animal 815 outbreaks are established, we recommend broad-based human outbreak investigations 816 that include all community members, not just the high-risk individuals, i.e., all individuals 817 who may have had contact with animal products from the affected herd, as well as 818 those who do not own livestock but reside in areas within vector flight range.

819 Gap 3: Differences in seasonality across endemic/enzootic locations. As 820 climate change modifies seasonal weather patterns, differences in outbreak incidence 821 are becoming more prominent among at-risk locations, but these changes may make 822 epidemics harder to predict. Eighty-nine (31%) of our included studies specifically 823 mention flooding at the outbreak site. A defined "rainy season" and "dry season" in 824 tropical locations can guide risk assessment, but it is not just rain that makes an 825 outbreak more likely. Congregation of many susceptible hosts and large volume slaughtering of animals (for example, as part of religious or community festivals [146, 826 827 176, 177]), an abundance of mosquito breeding containers (for example, in plastic 828 trash) [178], large-scale animal movement [179], and low baseline herd immunity will 829 increase the chance of RVFV outbreaks. Recent data-driven modeling efforts by 830 Hardcastle and colleagues [58], incorporating environmental and human and animal 831 census data at the district level, predict that outbreaks in southern and eastern Africa 832 are most likely to occur in December through July, whereas risk in the Sahelian zone

43

will be higher in September through November [180]. Even within countries, seasonal
rainfall can vary widely. For example, in western Kenya, August typically has above
average rainfall while the remainder of the country remains dry [181]. Real-time regional
level weather information must be considered to obtain adaptive implementation of
mitigation efforts.

838 Pastoralist herds tend to have higher RVFV exposure, and this is influenced by 839 the types of ecozones where the herds circulate. Pastoralists follow water and pasture 840 availability as they become available in a seasonal cycle, which may involve movement 841 through high-risk zones. As animal protein demand increases, mostly in urban centers, 842 more livestock will be passing through areas that have previously experienced RVF 843 cases, and in the presence of competent mosquito vectors. Recent infections are more 844 common in nomadic herds compared to agro-pastoralist herds [182] and in herds with 845 longer distance to travel to their night pens or to the nearest permanent water [82]. 846 Modeling of data from Senegal suggested that nomadic herd movements are sufficient 847 to account for endemic circulation of RVFV, although the co-existence of Aedes vertical 848 transmission cannot be ruled out [183].

In addition to climate, the variety of suitable hosts present in those areas will also vary from location to location. All potential wildlife reservoir species should be considered when comparing incidences between two geographically distinct areas because wild animals' behaviors and range is intimately tied to topography and resource availability. In Botswana, wildlife hunters' seroprevalence was 27% compared to a 3% community level exposure [35], showing that wildlife exposure may contribute directly to human burden independent of domestic livestock presence. This is further

44

illustrated by human case exposure in Angola without documented livestock exposure
[100]. As RVFV can adapt to new ecological niches and utilize a wide variety of
mammals to amplify itself, including common white-tail deer [184, 185], we caution not
to make the assumption that wild animals' role in RVFV transmission will be similar
between locations. All suitable wild animals, particularly wild ungulates, should in
included in calculations of regional herd immunity and their interface with humans
should be considered as a likely risk factor.

863 Gap 4: Data challenges related to bias based on limited study designs and 864 inconsistent reporting. A systematic review by Bron and colleagues [186] has 865 summarized the patchwork of data collected on RVFV epidemiology over the last 866 century, and has highlighted the lack of standardized reporting as the major challenge in 867 comparing data between locations. In our current systematic review, which focused 868 solely on studies from the last two decades, we confirm that uneven reporting remains a 869 significant problem. Improving study designs and sampling frameworks for RVFV is 870 challenging, in part due to the lack of funding opportunities during interepidemic periods. In outbreak reports, uncertain levels of ascertainment bias and possible diagnostic 871 872 misclassification, mean that case finding and resulting case counts have unclear 873 accuracy. 'Population at risk' numbers used in incidence and prevalence calculations 874 are often chosen based on outdated census data without true understanding of who is 875 at risk within a community. With many smaller, low-budget, short-term studies (rather 876 than large collaborative long-term efforts) the focus turns to identifying enough cases for 877 a meaningful statistical analysis, which means that some studies will test only high-risk

45

individuals working with animals. This likely excludes vulnerable populations who havenot yet been identified as being at high-risk.

Hospital-based surveys for hemorrhagic fever surveillance are an attractive tool because they do not require household field visits and blood samples are typically more available for testing [38, 40, 150-152, 187, 188]. Such sero-surveillance can be compared from year to year to gain retrospective insight on when transmission has occurred. However, as with most hospital-based studies, these efforts do not represent the population at large, so they likely underestimate true incidence and overestimate the percentage of cases with severe disease.

887 Gap 5: Delineating human risk factors. This meta-analysis of human risk 888 factors across multiple 1999-2021 studies confirm the increased RVFV infection risk 889 associated with male gender, general livestock care, contact with animal abortus, 890 butchering animals, and milking risks, identified in previous reviews and meta-analysis 891 [64, 189]. Not all of the studies in this systematic review were population-based, thus 892 the variable reporting of associations having 'statistical significance' may be attributed to 893 differences in study design, low sample size with lack of statistical power, and/or choice 894 of target populations.

In most places where RVFV outbreaks occur, lack of health care infrastructure impedes detailed description of human disease signs and performance of laboratory studies (including assessment of viral load and immunologic responses to infection), which might be predictive of severe disease or death. It is possible that other health comorbidities, such as concurrent HIV or hepatitis, can influence the presentation of RVFV disease, but these associations have not yet been widely studied. Further

46

descriptions of the natural history of clinical and laboratory findings in human RVF are
needed, and efforts should be made to fully assess the relative risks from direct (nonvector) animal exposures vs. mosquito vector-borne exposure. Frontline healthcare
workers need to recognize when testing for RVFV infection is appropriate, based on
patients' significant risk factors, and they should communicate frequently with local
veterinary colleagues to identify high-risk transmission periods.

907 Most risk factor analyses rely on participant recall, risking recall bias, and it has 908 been difficult to discriminate the risk of living in the presence of susceptible livestock 909 from risk due to direct participation in husbandry activities or from risk due to local 910 mosquito exposure (including variably zoophilic and anthropophilic mosquito species). 911 Aside from animal rearing activities, the association of human risk with consumption of 912 infected animal products is concerning, as this is practiced by a majority of human 913 populations and the true infectivity by consumption is still not well understood. For 914 example, consumption of raw milk is a now well recognized as an RVFV exposure risk 915 factor [64, 189], but no previous studies have isolated RVFV from milk during outbreaks. 916 Ongoing studies in Kenya (Gerken et al, unpublished), are conducting risk assessments 917 in urban areas to distinguish consumption risk factors versus risk from livestock rearing 918 activities common to rural areas.

919 RVF has been perceived as a disease of poverty, but this is likely due to its 920 greater incidence recognized in rural areas. It is not known whether RVFV has an urban 921 transmission cycle, and so far, the risk of RVF related to socioeconomic status (aside 922 from having a pastoralist lifestyle) is poorly defined. Choice of occupation is intimately 923 connected to socioeconomic status and this systematic review confirmed that the

47

highest-risk occupations are associated with livestock exposure. Even within
occupational categories, differences in assigned tasks can carry differential risks [190].
We combined common terminology for the same profession, for example,
slaughterhouse and abattoir workers for our analysis; however, more specific factors
such as size of the slaughterhouse, species slaughtered, and available personal
protective equipment (PPE) are likely strong confounding factors.

930

931 Gap 6: Need for consistent naming of RVFV lineages and strains. A possible 932 explanation for variation in RVF attack rates and disease severity, noted between 933 locations and among different hosts, could be differences in RVFV strain virulence. 934 Laboratory studies suggest some strain-specific differences in mortality in experimental 935 animals [191]. However, the variability observed during natural outbreaks is likely due to 936 site-related diagnostic misclassification of RVFV infection with erratic failure to detect 937 milder cases of disease. Our systematic review aimed to capture strain- and lineage-938 specific effects; however, a meaningful analysis was obscured by inconsistent naming 939 of lineages due to differences in the genetic sequences chosen to be studied and 940 different approaches to sequence homology analysis. International harmonization of 941 lineage identity and nomenclature will help to determine differential effects, if any, of 942 individual RVFV lineages and strains. As with SARS-CoV2 variants, a naming scheme 943 that does not rely on location may help to alleviate some of the disincentive and stigma 944 for national governments to report acute cases and identify sequences of circulating 945 genomes to identify sources of local introduction.

48

946 Gap 7: Need for consistent RVFV testing frameworks. As highlighted earlier, 947 identification of RVFV outbreaks and determination of the endemic state of a country 948 require consideration of the efficacy of surveillance efforts in place. Well organized and 949 implemented surveillance systems provide the basis for understanding the epidemiology 950 of RVFV and provide an opportunity to provide early warning and an opportunity to fill 951 the gaps in current knowledge. 952 As RVFV diagnostics become more widely available, physicians in 953 hyperendemic regions will be able to consider co-infection with RVFV in their differential 954 diagnoses, especially for pregnant mothers who are at risk for abortion [168]. 955 Additionally, if hospitals are aware of current RVFV circulation in livestock, they can go 956 on high-alert and intensify their screening of patients for RVF. However, the lack of 957 specific medical therapeutics may dissuade clinicians from testing for RVFV and favor 958 testing for more treatable conditions, notably malaria. As the recent experience with 959 Ebola virus in West Africa has taught, compassionate care must be the cornerstone of 960 outbreak response in order for the at-risk population to buy into control measures. 961 Public health messaging that fuels despair results in massive underreporting, 962 particularly if outbreaks become political [192]. 963 There are concerted efforts to create a pan-viral hemorrhagic fever diagnostic 964 assay. The Uganda Virus Research Institute (UVRI) in Entebbe has been implementing 965 laboratory-based surveillance for viral hemorrhagic fevers (VHF) in Uganda since 2010, 966 which includes testing for RVFV [193]. While this may help differentiate RVFV from other concerning viruses, we caution about the grouping of RVFV with other 967

968 hemorrhagic fevers for surveillance purposes, as RVF-related hemorrhage in humans is

49

969 the rarest clinical manifestation, and the risk factors for other forms of RVFV-related970 disease are different.

971 Development of robust RVFV surveillance systems is complex, because both 972 animals and humans display variably detectable disease outcomes when they become 973 infected. Currently, most RVFV surveillance systems are engaged only in response to 974 climate early warning systems and are focused on periods with high-risk for large scale 975 outbreaks. We found that recent re-structuring of the FAO Global Animal Disease 976 Information System (EMPRESi) has provided an open-source, easy to navigate platform 977 for tracking reports of RVFV cases in member countries. Since 2004, the system has 978 recorded 1,186 animal cases of RVFV, of which 1,175 were confirmed. This reporting 979 system relies on mandatory reporting of acute cases by national authorities, the OIE, 980 WHO, FAO field officers, and published reports such as those included in this review. 981 However, this database excludes longitudinal seroconversions, and therefore, excludes 982 evidence of sub-clinical transmission during interepidemic periods. Modeling 983 approaches using only these data should consider this key missing piece in their 984 assumptions. Although RVFV is a reportable disease in many of the affected countries, 985 a system that relies on passive reporting is likely to miss areas of new emergence when 986 viral activity is below the threshold to detect excess numbers of patients with the more 987 obvious clinical signs of RVF. It should be noted that the partnership of a strong national 988 veterinary service with close ties to a fully equipped national laboratory is crucial to any 989 successful surveillance effort. If farmer-based cellphone reporting is to be successful at 990 identifying RVF cases, farmers need to be sensitized to the greater goals of the system 991 and incentivized to report. Overall, the ideal surveillance system for RVFV would utilize

50

aspects of each of the discussed surveillance types (Fig 10), focusing on sentinels and 992 993 enhanced active case finding, including during interepidemic periods, and take into 994 account regional differences in animal and human health systems. Since RVFV is a 995 vector-transmitted disease, and a large proportion of the world has the potential for 996 RVFV emergence, the management of RVFV surveillance efforts should be regionally 997 collaborated and all RVFV-naive countries with large numbers of livestock should take 998 into account past lessons about recent new geographic introduction as they prepare 999 prevention and mitigation efforts for themselves [194-199].

1000 Post-epidemic performance analyses have found that the lead time given by 1001 early warning systems may not be sufficiently long to prepare and vaccinate enough 1002 livestock to contain an outbreak. Just as reliance on a passive surveillance system for 1003 RVFV is likely to not be enough to detect outbreaks, sole reliance on a remotely sensed 1004 early warning systems (EWS) should also be avoided. One major limitation of climatic 1005 EWS is that they do not account for the effect of herd immunity, either through natural 1006 infection or prior livestock vaccination. Livestock seroprevalence as high as 60% have 1007 been captured in high risk areas [200] and up to 38% in areas that are not typically 1008 classified as high risk, such as Chad [201]. The lack of outbreak detection, despite 1009 seemingly high-risk weather conditions, can be explained both by the effect of herd 1010 immunity and limitations of existing surveillance systems. With this current level of 1011 performance, at-risk countries should not rely solely on early warning systems and 1012 instead use them as part of integrated decision support tools, similar to those developed 1013 for the greater Horn of Africa [202]. As RVFV outbreaks have often had an insidious

51

1014 onset, we recommend active case finding in high-risk areas in response to any of the1015 previously mentioned early warning signals.

1016 Gap 8: Evolving better approaches to diagnostics. Because arboviral 1017 infections such as RVF often result in self-limited febrile syndromes with non-specific 1018 signs and symptoms, isolated cases of infection are frequently misdiagnosed as malaria 1019 in sub-Saharan Africa. This highlights the critical need for affordable and accurate point-1020 of-care diagnostics for RVFV [203-206]. In the majority of recent transmission surveys, 1021 anti-RVFV IgM serology was used alone to define recent infection, and more humans 1022 than animals were found to be positive. As commercial IgM ELISA tests are now more 1023 widely available for livestock, this gap likely represents a lack of available resources, 1024 either financial or logistical, for testing livestock for recent infection. For suspect acute 1025 cases, IgM allows a wider window of detection than discovery of circulating virus or viral 1026 RNA [207].

1027 Among the 95 studies that reported human serology, the methods for human 1028 anti-RVFV antibody detection exhibited significant variability, with most studies relying 1029 on tertiary reference laboratories for final diagnosis. Future efforts should focus on 1030 increasing the number and capacity of local laboratories so that the burden of shipping 1031 time and costs can be alleviated. The Covid-19 pandemic response has led to 1032 expansion of molecular diagnostic capacity in many regions. In the aftermath of the 1033 pandemic, these important logistical and laboratory resources should be leveraged to 1034 include other viral diseases such as RVF.

Serology serves as the basic approach for investigating individual and
 community level risk factors as it can monitor changes in prevalence over time. Both

52

enzyme-linked immunosorbent assays (ELISA) and viral neutralization tests (VNT) have
advantages and disadvantages. Identifying IgG-positive livestock by ELISA has often
been the first step in recognizing new areas of emergence [80, 208]. However, follow up
VNT should be used to confirm positive ELISA results in new locations, especially if the
seroprevalence is low (less than 1-2%) when misclassification due to false-positive tests
is of concern.

1043

### Gap 9: The need for One Health approaches for RVFV detection and

1044 **control.** Expanding RVFV surveys to include human community populations at-large 1045 will identify risk associated with socioeconomic standing, while simultaneously detecting 1046 patients with incident infections but without presently known risk factors. To fully 1047 understand the ecology of local transmission such broad-based human studies need to 1048 be conducted concurrently with robust animal surveys. Recent reviews and policy 1049 papers in the human and animal health RVFV literature call for a greater emphasis on a 1050 One Health management approach, both in research and control efforts [127, 209, 210]. 1051 A better understanding of viral transmission to all species during interepidemic periods, 1052 with an improvement of diagnostic sampling frameworks, are within reach in the next 1053 decade. Reaching an understanding of the herd immunity threshold for outbreak 1054 initiation, the variability in case fatality risks, the contributions of vectors to both 1055 asymptomatic and symptomatic human and animal infections, and the most influential 1056 transmission pathways will take a collaborative effort among multiple disciplines and 1057 public health sectors. The gaps presented here are based on a collated estimates of 1058 recent RVFV transmission. The available case counts and serosurveys in this

53

systematic review contribute to a body of evidence that can guide the way forward toclinical testing of novel preventive and curative interventions.

1061 **Summary.** RVFV continues to transmit across Africa and nearby Indian Ocean 1062 islands at a high rate, but at an irregular frequency. As previously noted, because of its 1063 typical mosquito-borne re-emergent transmission, RVFV outbreaks often follow periods of excess rainfall and local flooding, particularly in semi-arid regions. During the 1999-1064 2021 period studied in this review, animal and human outbreaks of RVF occurred at an 1065 1066 average rate of 5-6 events per year across the region. The range of transmission has 1067 expanded, with human cases documented for the first time in Saudi Arabia, Yemen, 1068 Comoros, Mayotte, Burundi, Niger, and Mali, and with re-emergence in Uganda after 1069 multiple decades of no activity. Reported human RVF events were most common in 1070 Mauritania, Kenya, Sudan, Madagascar, and South Africa, and each of these countries 1071 experienced multiple epidemics since 1999. In districts or counties where human cases 1072 were reported, the median attack rate was 2.6 per 100,000 (range 0.1 to 91), and 1073 median case fatality was 14.1% of severe cases, highlighting the significant population 1074 health burden of RVF.

Experience with veterinary vaccines indicates that pre-event vaccination can mitigate the spread of RVFV infection. Now that human vaccines are under development, and their clinical testing and implementation should be guided by particular focus on the high-risk subgroups (based on location and exposures) identified in this review. Effective vaccine trials will depend on achieving accurate outbreak predictions combined with efficient animal and human case surveillance systems.

## 1082 Acknowledgments

- 1083 The authors would like to acknowledge the very helpful guidance provided by members
- 1084 of the CEPI literature review advisory group: Dr. Brian Bird, Dr. Baptiste Dungu, Roice
- 1085 Fulton, Dr. Jeroen Kortekaas, Dr. Paul Oloo, Dr. Janusz Paweska, Dr. Melinda Rostal,
- 1086 and Dr. George Warimwe.
- 1087 We also acknowledge the assistance of RVFV research collaborators who provided
- 1088 their unpublished survey data for inclusion in this study: Garja S. Suner, Pius S. Ekong,
- 1089 Elysse N. Grossi-Soyster, Mabel K. Aworh, Yiltawe S. Wungak, Nanven A. Maurice,
- 1090 Michael J. Ekong, and Bonto Faburay.
- 1091

### 1092 Figure legends

1093 Fig 1. PRISMA systematic review flow diagram of data collection and evaluation 1094 Online searches for publications and data registers (left side flow) were supplemented 1095 by governmental outbreak reports, non-indexed citations found in local archives, and 1096 citations found within the reference lists of the papers that were reviewed (right side 1097 flow). Data from one unpublished study were also included for evaluation. 1098 1099 Fig 2. Regional map of countries exposed to RVFV infection based on findings of 1100 studies included in the systematic review. Countries were categorized as to whether 1101 there was evidence of human, animal, or insect RVFV infection during the 1999-2021 1102 era. 1103 1104 Fig 3. Sub-national administrative regions experiencing acute human cases of 1105 **RVF during the years 1999-2021** Locations are shaded according to whether they 1106 experienced outbreaks before or after 2011, or if they had outbreaks during both 1107 periods of time. 1108 1109 Fig 4. Sub-national administrative regions experiencing acute animal cases of 1110 **RVF during the years 1999-2021** Locations are shaded according to whether they 1111 experienced outbreaks before or after 2011, or during both periods of time. 1112 1113 Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions 1114 across Africa, the Indian Ocean, and the Arabian Peninsula 1115

- 1116Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions1117across Africa, the Indian Ocean, and the Arabian Peninsula
- 1118

1119Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in1120at-risk populations

1121

1122Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure1123in at-risk populations.

1124

Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on odds of human RVFV exposure in at-risk populations

1127

1128Fig 10 Progressive scale of surveillance that can used to indicate an impending

- 1129 **RVFV disease outbreak.** Republished with permission of The National Academies
- 1130 Press, from Under the Weather: Climate, Ecosystems, and Infectious Disease (2001),
- 1131 Chapter 7: Towards the Development of Disease Early Warning Systems. P. 87;
- 1132 permission conveyed through Copyright Clearance Center, Inc. under license ID
- 1133 **#1142222**
- 1134
- 1135

### 56

# 1136 **References**

1137 1. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health 1138 problems. Arch Med Res. 2002;33(4):330-342. Epub 2002/09/18. doi: 10.1016/s0188-1139 4409(02)00378-8.

1140

- 1141 2. CDC. Rift Valley Fever. Viral Hemorrhagic Fevers: Fact Sheets. 2021:1-3. Available 1142 from https://www.cdc.gov/vhf/index.html
- 1143
- 1144
  3. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis.
  1145
  2001;33(10):1707-1712. Epub 2001/10/12. doi: 10.1086/322620.
- 1146
- 1147 4. WHO. Rift Valley Fever. WHO Fact Sheet No 207. 2018:1-5. Epub 19 Feb 2018.

1148

- 5. Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, et al. Rift Valley fever outbreak in livestock in Kenya, 2006-2007. Am J Trop Med Hyg. 2010;83(2)
- 1151 Suppl):58-64. Epub 2010/08/13. doi: 10.4269/ajtmh.2010.09-0292.

1152

- 1153 6. CDC. Outbreak of Rift Valley fever--Yemen, August-October 2000. MMWR.
- 1154 2000;49(47):1065-1066.

1155

- 1156 7. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, et al. An
- 1157 outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg Infect Dis.
- 1158 2002;8(2):138-144. Epub 2002/03/19. doi: 10.3201/eid0802.010023.

1159

- 1160 8. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever: an
- undescribed virus disease of sheep, cattle and man from East Africa. Journal ofPathology and Bacteriology. 1931;34:545-579.
- Pathology and Bacteriology. 1931;34:5

1163

9. CDC. Update: Outbreak of Rift Valley Fever - Saudi Arabia, August-November 2000.MMWR. 2000;49(43):982-985.

1166

- 1167 10. Golnar AJ, Turell MJ, LaBeaud AD, Kading RC, Hamer GL. Predicting the mosquito 1168 species and vertebrate species involved in the theoretical transmission of Rift Valley
- 1169 fever virus in the United States. PLoS Negl Trop Dis. 2014;8(9):e3163. doi:
- 1170 10.1371/journal.pntd.0003163.

1172 1173 1174	11. Iranpour M, Turell MJ, Lindsay LR. Potential for Canadian mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc. 2011;27(4):363-369. Epub 2012/02/15. doi: 10.2987/11-6169.1.
1175 1176 1177 1178	12. Turell MJ, Dohm DJ, Geden CJ, Hogsette JA, Linthicum KJ. Potential for stable flies and house flies (Diptera: Muscidae) to transmit Rift Valley fever virus. J Am Mosq Control Assoc. 2010;26(4):445-448. Epub 2011/02/05. doi: 10.2987/10-6070.1.
1179 1180 1181 1182	<ol> <li>Turell MJ, Wilson WC, Bennett KE. Potential for North American mosquitoes (Diptera: Culicidae) to transmit Rift Valley fever virus. J Med Entomol. 2010;47(5):884- 889. Epub 2010/10/14. doi: 10.1603/me10007.</li> </ol>
1183 1184 1185 1186	14. Gargan TP, 2nd, Clark GG, Dohm DJ, Turell MJ, Bailey CL. Vector potential of selected North American mosquito species for Rift Valley fever virus. Am J Trop Med Hyg. 1988;38(2):440-446. doi: 10.4269/ajtmh.1988.38.440.
1187 1188 1189	15. Turell MJ, Bailey CL, Beaman JR. Vector competence of a Houston, Texas strain of <i>Aedes albopictus</i> for Rift Valley fever virus. J Am Mosq Control Assoc. 1988;4(1):94-96.
1190 1191 1192 1193	16. Chengula AA, Mdegela RH, Kasanga CJ. Socio-economic impact of Rift Valley fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in Tanzania. Springerplus. 2013;2:549. Epub 2013/11/21. doi: 10.1186/2193-1801-2-549.
1194 1195 1196 1197	17. Holleman C. The socio-economic implications of the livestock ban in Somaliland. Food Early Warning System, Assessment Mission to Somaliland. FEWS NET, Nairobi 2002.
1198 1199 1200 1201	<ol> <li>Muga GO, Onyango-Ouma W, Sang R, Affognon H. Sociocultural and economic dimensions of Rift Valley fever. Am J Trop Med Hyg. 2015;92(4):730-738. Epub 2015/02/18. doi: 10.4269/ajtmh.14-0363.</li> </ol>
1202 1203 1204 1205	19. Rich KM, Wanyoike F. An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg. 2010;83(2 Suppl):52-57. doi: 10.4269/ajtmh.2010.09-0291.
1206 1207 1208 1209	20. Riou O, Phillipe B, Jouan A, Coulibaly I, Mondo M, Digoutte JP. Les formes neurologiques et neurosensorielles de la fievre de Valley du Rift en Mauritanie. Bulletin de la Societe de Phologie Exotiques. 1989;82:605-610.
1210	

21. Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK, et al. Severe

1211

- 1212 Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med 1213 Hyg. 2010;82(3):371-375. doi: 10.4269/ajtmh.2010.09-0669. 1214 1215 22. Kim Y, Metras R, Dommergues L, Youssouffi C, Combo S, Le Godais G, et al. The 1216 role of livestock movements in the spread of Rift Valley fever virus in animals and 1217 humans in Mayotte, 2018-19. PLoS Negl Trop Dis. 2021;15(3):e0009202. doi: 1218 10.1371/journal.pntd.0009202. 1219 1220 23. OIE. Rift Valley Fever (RVF): OIE; 2021. Available from: 1221 https://www.oie.int/en/animal-health-in-the-world/animal-diseases/rift-valley-fever/. 1222 1223 24. Davies FG, Linthicum KJ, James AD. Rainfall and epizootic Rift Valley Fever. Bull 1224 World Health Organ. 1985;63:941-943. 1225 1226 25. Linthicum KJ, Anyamba A, Tucker CJ, Kelley PW, Myers MF, Peters CJ. Climate 1227 and satellite indicators to forecast Rift Valley fever epidemics in Kenya. Science. 1228 1999;285:397-400. 1229 1230 26. Linthicum KJ, Bailey CL, Davies FG, Tucker CJ. Detection of Rift Valley fever viral 1231 activity in Kenya by satellite remote sensing imagery. Science. 1987;235(4796):1656-1232 1659. Epub 1987/03/27. 1233 1234 27. Linthicum KJ, Bailey CL, Tucker CJ, Mitchell KD, Logan TM, Davies FG, et al. 1235 Application of polar-orbiting, meteorological satellite data to detect flooding of Rift Valley 1236 fever virus vector mosquito habitats in Kenya. Med Vet Entomol. 1990;4(4):433-438. 1237 Epub 1990/10/01. 1238 1239 28. Anyamba A, Chretien JP, Formenty PB, Small J, Tucker CJ, Malone JL, et al. Rift 1240 Valley fever potential, Arabian Peninsula. Emerg Infect Dis. 2006;12(3):518-520. Epub 1241 2006/05/23. doi: 10.3201/eid1203.050973. 1242 1243 29. Anyamba A, Chretien JP, Small J, Tucker CJ, Formenty PB, Richardson JH, et al. 1244 Prediction of a Rift Valley fever outbreak. Proc Natl Acad Sci U S A. 2009;106(3):955-1245 959. doi: 10.1073/pnas.0806490106. 1246 1247 30. Anyamba A, Chretien JP, Small J, Tucker CJ, Linthicum KJ. Developing global
- 1247 30. Anyamba A, Chretten JP, Small J, Tucker CJ, Linthicum KJ. Developing global 1248 climate anomalies suggest potential disease risks for 2006-2007. Int J Health Geogr.
- 1249 2006;5:60. Epub 2006/12/30. doi: 10.1186/1476-072x-5-60.

59

1250 1251 1252 1253 1254	31. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, et al. Prediction, assessment of the Rift Valley fever activity in East and southern Africa 2006- 2008 and possible vector control strategies. Am J Trop Med Hyg. 2010;83(2 Suppl):43- 51. doi: 10.4269/ajtmh.2010.09-0289.
1255 1256 1257 1258	32. Anyamba A, Linthicum KJ, Tucker CJ. Climate-disease connections: Rift Valley fever in Kenya. Cad Saude Publica. 2001;17 Suppl:133-140. Epub 2001/06/27. doi: 10.1590/s0102-311x2001000700022.
1259 1260 1261 1262 1263	33. Ahmed A, Makame J, Robert F, Julius K, Mecky M. Sero-prevalence and spatial distribution of Rift Valley fever infection among agro-pastoral and pastoral communities during interepidemic period in the Serengeti ecosystem, northern Tanzania. BMC Infect Dis. 2018;18(1):276. Epub 2018/06/15. doi: 10.1186/s12879-018-3183-9.
1264 1265 1266 1267 1268	34. Tigoi C, Sang R, Chepkorir E, Orindi B, Arum SO, Mulwa F, et al. High risk for human exposure to Rift Valley fever virus in communities living along livestock movement routes: A cross-sectional survey in Kenya. PLoS Negl Trop Dis. 2020;14(2):e0007979. Epub 2020/02/23. doi: 10.1371/journal.pntd.0007979.
1269 1270 1271 1272	35. Sanderson CE, Jori F, Moolla N, Paweska JT, Oumer N, Alexander KA. Silent circulation of Rift Valley fever in humans, Botswana, 2013-2014. Emerg Infect Dis. 2020;26(10):2453-2456. Epub 2020/09/19. doi: 10.3201/eid2610.191837.
1273 1274 1275 1276	36. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerging Infectious Diseases. 2014;20(7):1176-1182. doi: 10.3201/eid2007.131265.
1277 1278 1279 1280	37. Bosworth A, Ghabbari T, Dowall S, Varghese A, Fares W, Hewson R, et al. Serologic evidence of exposure to Rift Valley fever virus detected in Tunisia. New Microbes New Infect. 2016;9:1-7. doi: 10.1016/j.nmni.2015.10.010.
1281 1282 1283 1284 1285	38. Dellagi K, Salez N, Maquart M, Larrieu S, Yssouf A, Silai R, et al. Serological evidence of contrasted exposure to arboviral infections between islands of the Union of Comoros (Indian Ocean). PloS Neglected Tropical Diseases. 2016;10(12). doi: 10.1371/journal.pntd.0004840.
1286 1287 1288 1289	39. Durand JP, Bouloy M, Richecoeur L, Peyrefitte CN, Tolou H. Rift Valley fever virus infection among French troops in Chad. Emerg Infect Dis. 2003;9(6):751-752. Epub 2003/06/05. doi: 10.3201/eid0906.020647.

1290 1291 1292 1293 1294 1295	40. Guillebaud J, Bernardson B, Randriambolamanantsoa TH, Randrianasolo L, Randriamampionona JL, Marino CA, et al. Study on causes of fever in primary healthcare center uncovers pathogens of public health concern in Madagascar. PLoS Negl Trop Dis. 2018;12(7):e0006642. Epub 2018/07/17. doi: 10.1371/journal.pntd.0006642.
1296 1297 1298 1299 1300	41. Gudo ES, Pinto G, Weyer J, le Roux C, Mandlaze A, José AF, et al. Serological evidence of rift valley fever virus among acute febrile patients in Southern Mozambique during and after the 2013 heavy rainfall and flooding: implication for the management of febrile illness. Virol J. 2016;13:96. Epub 2016/06/10. doi: 10.1186/s12985-016-0542-2.
1301 1302 1303 1304	42. Sow A, Faye O, Faye O, Diallo D, Sadio BD, Weaver SC, et al. Rift Valley fever in Kedougou, southeastern Senegal, 2012. Emerg Infect Dis. 2014;20(3):504-506. Epub 2014/02/26. doi: 10.3201/eid2003.131174.
1305 1306 1307 1308	43. Sumaye RD, Abatih EN, Thiry E, Amuri M, Berkvens D, Geubbels E. Inter-epidemic acquisition of Rift Valley fever virus in humans in Tanzania. PLoS Negl Trop Dis. 2015;9(2):e0003536. Epub 2015/02/28. doi: 10.1371/journal.pntd.0003536.
1309 1310 1311 1312	44. Liu J, Sun Y, Shi W, Tan S, Pan Y, Cui S, et al. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerg Microbes Infect. 2017;6(1):e4. Epub 2017/01/18. doi: 10.1038/emi.2016.136.
1313 1314 1315 1316 1317	45. Oltmann A, Kämper S, Staeck O, Schmidt-Chanasit J, Günther S, Berg T, et al. Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV vaccination and evidence of Rift Valley fever virus infection. J Clin Microbiol. 2008;46(11):3850-3852. Epub 2008/09/05. doi: 10.1128/jcm.01102-08.
1318 1319 1320 1321	46. Evans A, Gakuya F, Paweska JT, Rostal M, Akoolo L, Van Vuren PJ, et al. Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiology and Infection. 2008;136(9):1261-1269. doi: 10.1017/S0950268807009806.
1322 1323 1324 1325 1326	47. LaBeaud AD, Cross PC, Getz WM, Glinka A, King CH. Rift Valley fever virus infection in African Buffalo ( <i>Syncerus caffer</i> ) herds in rural South Africa: Evidence of interepidemic transmission. American Journal of Tropical Medicine and Hygiene. 2011;84(4):641-646. doi: 10.4269/ajtmh.2011.10-0187.
1327	

61

1328 48. Olive MM, Goodman SM, Reynes JM. The role of wild mammals in the 1329 maintenance of Rift Valley fever virus. J Wildl Dis. 2012;48(2):241-266. doi: 1330 10.7589/0090-3558-48.2.241. 1331 1332 49. Rostal MK, Evans AL, Sang R, Gikundi S, Wakhule L, Munyua P, et al. 1333 Identification of potential vectors of and detection of antibodies against Rift Valley fever 1334 virus in livestock during interepizootic periods. American Journal of Veterinary 1335 Research. 2010;71(5):522-526. doi: 10.2460/ajvr.71.5.522. 1336 1337 50. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 1338 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. 1339 Bmj. 2021;372:n71. doi: 10.1136/bmj.n71. 1340 1341 51. García-Bocanegra I, Paniagua J, Cano-Terriza D, Arenas-Montes A, Fernández-1342 Morente M, Napp S. Absence of Rift Valley fever virus in domestic and wild ruminants 1343 from Spain. Vet Rec. 2016;179(2):48. Epub 2016/05/11. doi: 10.1136/vr.103696. 1344 1345 52. Mentaberre G, Gutierrez C, Rodriguez NF, Joseph S, Gonzalez-Barrio D, Cabezon 1346 O, et al. A transversal study on antibodies against selected pathogens in dromedary 1347 camels in the Canary Islands, Spain. Veterinary Microbiology. 2013;167(3-4):468-473. 1348 doi: 10.1016/j.vetmic.2013.07.029. 1349 1350 53. Bazanow BA, Stygar D, Romuk E, Skrzep-Poloczek B, Pacon J, Gadzala L, et al. 1351 Preliminary serological investigation of Rift Valley fever in Poland. Journal of Vector 1352 Borne Diseases. 2018;55(4):324-326. doi: 10.4103/0972-9062.256570. 1353 1354 54. Kim HJ, Park JY, Jeoung HY, Yeh JY, Cho YS, Choi JS, et al. Serological surveillance studies confirm the Rift Valley fever virus free status in South Korea. Trop 1355 1356 Anim Health Prod. 2015;47(7):1427-1430. doi: 10.1007/s11250-015-0858-8. 1357 1358 55. Batieha A, Saliba EK, Graham R, Mohareb E, Hijazi Y, Wijeyaratne P. Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan. 1359 1360 Emerg Infect Dis. 2000;6(4):358-362. Epub 2000/07/25. doi: 10.3201/eid0604.000405. 1361 1362 56. Freeman MC, Garn JV, Sclar GD, Boisson S, Medlicott K, Alexander KT, et al. The impact of sanitation on infectious disease and nutritional status: A systematic review 1363 1364 and meta-analysis. Int J Hyg Environ Health. 2017;220(6):928-949. doi: 1365 10.1016/j.ijheh.2017.05.007. 1366

1367 1368 1369	57. Puzzolo E, Pope D, Stanistreet D, Rehfuess EA, Bruce NG. Clean fuels for resource-poor settings: A systematic review of barriers and enablers to adoption and sustained use. Environ Res. 2016;146:218-234. doi: 10.1016/j.envres.2016.01.002.
1370 1371 1372 1373 1374	58. Hardcastle AN, Osborne JCP, Ramshaw RE, Hulland EN, Morgan JD, Miller-Petrie MK, et al. Informing Rift Valley fever preparedness by mapping seasonally varying environmental suitability. Int J Infect Dis. 2020;99:362-372. Epub 2020/08/02. doi: 10.1016/j.ijid.2020.07.043.
1375 1376 1377 1378	59. Redding DW, Tiedt S, Lo Iacono G, Bett B, Jones KE. Spatial, seasonal and climatic predictive models of Rift Valley fever disease across Africa. Philos Trans R Soc Lond B Biol Sci. 2017;372(1725). Epub 2017/06/07. doi: 10.1098/rstb.2016.0165.
1379 1380 1381 1382 1383	60. Williams R, Malherbe J, Weepener H, Majiwa P, Swanepoel R. Anomalous high rainfall and soil saturation as combined risk indicator of Rift Valley fever outbreaks, South Africa, 2008-2011. Emerg Infect Dis. 2016;22(12):2054-2062. Epub 2016/07/13. doi: 10.3201/eid2212.151352.
1384 1385 1386 1387 1388	61. Hightower A, Kinkade C, Nguku PM, Anyangu A, Mutonga D, Omolo J, et al. Relationship of climate, geography, and geology to the incidence of Rift Valley fever in Kenya during the 2006-2007 outbreak. American Journal of Tropical Medicine and Hygiene. 2012;86(2):373-380. doi: 10.4269/ajtmh.2012.11-0450.
1389 1390 1391 1392 1393	62. Verster AM, Liang JE, Rostal MK, Kemp A, Brand RF, Anyamba A, et al. Selected wetland soil properties correlate to Rift Valley fever livestock mortalities reported in 2009-10 in central South Africa. PLoS One. 2020;15(5):e0232481. Epub 2020/05/19. doi: 10.1371/journal.pone.0232481.
1394 1395 1396 1397 1398	63. Sindato C, Pfeiffer DU, Karimuribo ED, Mboera LE, Rweyemamu MM, Paweska JT. A spatial analysis of Rift Valley fever virus seropositivity in domestic ruminants in Tanzania. PLoS One. 2015;10(7):e0131873. Epub 2015/07/15. doi: 10.1371/journal.pone.0131873.
1399 1400 1401 1402	64. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis. Trop Med Int Health. 2014;19(12):1420-1429. doi: 10.1111/tmi.12385.
1403 1404 1405 1406	65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. Epub 2002/07/12. doi: 10.1002/sim.1186.
1400	

63

1407 1408 1409 1410	66. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, editors. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Books; 2001. p. 285-312.
1411 1412 1413 1414 1415	67. Clark MHA, Warimwe GM, Di Nardo A, Lyons NA, Gubbins S. Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016. PloS Neglected Tropical Diseases. 2018;12(7). doi: 10.1371/journal.pntd.0006627.
1416 1417 1418 1419	68. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, et al. Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. Emerg Infect Dis. 2008;14(8):1240-1246. doi: 10.3201/eid1408.080082.
1420 1421 1422 1423	69. McElroy AK, Albariño CG, Nichol ST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol J. 2009;6:125. Epub 2009/08/15. doi: 10.1186/1743-422x-6-125.
1424 1425 1426 1427	70. Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J Virol Methods. 2005;124(1-2):173-181. Epub 2005/01/25. doi: 10.1016/j.jviromet.2004.11.020.
1428 1429 1430 1431 1432	71. Paweska JT, Jansen van Vuren P, Swanepoel R. Validation of an indirect ELISA based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection of IgG antibody in humans. J Virol Methods. 2007;146(1-2):119-124. Epub 2007/07/25. doi: 10.1016/j.jviromet.2007.06.006.
1433 1434 1435 1436 1437	<ol> <li>Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA. J Virol Methods. 2009;157(1):15-24. Epub 2009/01/07. doi: 10.1016/j.jviromet.2008.12.003.</li> </ol>
1438 1439 1440 1441	73. Wichgers Schreur PJ, Paweska JT, Kant J, Kortekaas J. A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test. J Virol Methods. 2017;248:26-30. doi: 10.1016/j.jviromet.2017.06.001.
1442 1443 1444 1445 1446	74. Sobarzo A, Paweska JT, Herrmann S, Amir T, Marks RS, Lobel L. Optical fiber immunosensor for the detection of IgG antibody to Rift Valley fever virus in humans. Journal of Virological Methods. 2007;146(1-2):327-334. doi: 10.1016/j.jvjromet.2007.07.017.

1446 10.1016/j.jviromet.2007.07.017.

64

1447 1448 1449 1450 1451	75. van der Wal FJ, Achterberg RP, de Boer SM, Boshra H, Brun A, Maassen CB, et al. Bead-based suspension array for simultaneous detection of antibodies against the Rift Valley fever virus nucleocapsid and Gn glycoprotein. J Virol Methods. 2012;183(2):99- 105. doi: 10.1016/j.jviromet.2012.03.008.
1452 1453 1454 1455	76. Petrova V, Kristiansen P, Norheim G, Yimer SA. Rift valley fever: diagnostic challenges and investment needs for vaccine development. BMJ Glob Health. 2020;5(8). Epub 2020/08/21. doi: 10.1136/bmjgh-2020-002694.
1456 1457 1458 1459 1460	77. Beechler BR, Manore CA, Reininghaus B, O'Neal D, Gorsich EE, Ezenwa VO, et al. Enemies and turncoats: bovine tuberculosis exposes pathogenic potential of Rift Valley fever virus in a common host, African buffalo ( <i>Syncerus caffer</i> ). Proc Biol Sci. 2015;282(1805). Epub 2015/03/20. doi: 10.1098/rspb.2014.2942.
1461 1462 1463 1464	78. Capobianco Dondona A, Aschenborn O, Pinoni C, Di Gialleonardo L, Maseke A, Bortone G, et al. Rift Valley fever virus among wild ruminants, Etosha National Park, Namibia, 2011. Emerg Infect Dis. 2016;22(1):128-130. doi: 10.3201/eid2201.150725.
1465 1466 1467 1468	79. Sindato C, Swai ES, Karimuribo ED, Dautu G, Pfeiffer DU, Mboera LEG, et al. Spatial distribution of non-clinical Rift Valley fever viral activity in domestic and wild ruminants in northern Tanzania. Tanzania Veterinary Journal. 2013;28 (Special):21-38.
1469 1470 1471 1472	80. Selmi R, Mamlouk A, Ben Said M, Ben Yahia H, Abdelaali H, Ben Chehida F, et al. First serological evidence of the Rift Valley fever Phlebovirus in Tunisian camels. Acta Trop. 2020;207:105462. Epub 2020/04/24. doi: 10.1016/j.actatropica.2020.105462.
1473 1474 1475 1476 1477	81. Di Nardo A, Rossi D, Saleh SM, Lejlifa SM, Hamdi SJ, Di Gennaro A, et al. Evidence of Rift Valley fever seroprevalence in the Sahrawi semi-nomadic pastoralist system, Western Sahara. BMC Vet Res. 2014;10:92. Epub 2014/04/25. doi: 10.1186/1746-6148-10-92.
1478 1479 1480 1481 1482	82. Kanouté YB, Gragnon BG, Schindler C, Bonfoh B, Schelling E. Epidemiology of brucellosis, Q Fever and Rift Valley fever at the human and livestock interface in northern Côte d'Ivoire. Acta Trop. 2017;165:66-75. Epub 2016/02/24. doi: 10.1016/j.actatropica.2016.02.012.
1483 1484 1485 1486	83. Andayi F, Charrel RN, Kieffer A, Richet H, Pastorino B, Leparc-Goffart I, et al. A sero-epidemiological study of arboviral fevers in Djibouti, Horn of Africa. PLoS Negl Trop Dis. 2014;8(12):e3299. Epub 2014/12/17. doi: 10.1371/journal.pptd.0003299

1486 Trop Dis. 2014;8(12):e3299. Epub 2014/12/17. doi: 10.1371/journal.pntd.0003299.

1487 1488 1489 1490	84. Umuhoza T, Berkvens D, Gafarasi I, Rukelibuga J, Mushonga B, Biryomumaisho S. Seroprevalence of Rift Valley fever in cattle along the Akagera-Nyabarongo rivers, Rwanda. J S Afr Vet Assoc. 2017;88(0):e1-e5. doi: 10.4102/jsava.v88i0.1379.
1491 1492 1493 1494 1495	85. Dutuze MF, Ingabire A, Gafarasi I, Uwituze S, Nzayirambaho M, Christofferson RC. Identification of Bunyamwera and possible other Orthobunyavirus infections and disease in cattle during a Rift Valley fever outbreak in Rwanda in 2018. Am J Trop Med Hyg. 2020;103(1):183-189. Epub 2020/04/22. doi: 10.4269/ajtmh.19-0596.
1496 1497 1498 1499 1500	86. Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, et al. Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana. PLoS Negl Trop Dis. 2013;7(9):e2435. Epub 2013/09/27. doi: 10.1371/journal.pntd.0002435.
1501 1502 1503 1504 1505	87. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, et al. Multiple virus lineages sharing recent common ancestry were associated with a large Rift Valley fever outbreak among livestock in Kenya during 2006-2007. J Virol. 2008;82(22):11152-11166. doi: 10.1128/JVI.01519-08.
1506 1507 1508 1509 1510	88. Miller BR, Godsey MS, Crabtree MB, Savage HM, Al-Mazrao Y, Al-Jeffri MH, et al. Isolation and genetic characterization of Rift Valley fever virus from <i>Aedes vexans</i> <i>arabiensis</i> , Kingdom of Saudi Arabia. Emerg Infect Dis. 2002;8(12):1492-1494. Epub 2002/12/25. doi: 10.3201/eid0812.020194.
1511 1512 1513 1514	89. Nderitu L, Lee JS, Omolo J, Omulo S, O'Guinn ML, Hightower A, et al. Sequential Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus. J Infect Dis. 2011;203(5):655-665. doi: 10.1093/infdis/jiq004.
1515 1516 1517 1518 1519 1520	90. Maquart M, Pascalis H, Abdouroihamane S, Roger M, Abdourahime F, Cardinale E, et al. Phylogeographic reconstructions of a Rift Valley fever virus strain reveals transboundary animal movements from eastern continental Africa to the Union of the Comoros. Transbound Emerg Dis. 2016;63(2):e281-285. Epub 2014/09/13. doi: 10.1111/tbed.12267.
1521 1522 1523 1524 1525 1526	91. Ratovonjato J, Olive MM, Tantely LM, Andrianaivolambo L, Tata E, Razainirina J, et al. Detection, isolation, and genetic characterization of Rift Valley fever virus from <i>Anopheles (Anopheles) coustani, Anopheles (Anopheles) squamosus</i> , and <i>Culex (Culex) antennatus</i> of the Haute Matsiatra region, Madagascar. Vector Borne Zoonotic Dis. 2011;11(6):753-759. Epub 2010/10/30. doi: 10.1089/vbz.2010.0031.

66

- 1528 92. Andriamandimby SF, Randrianarivo-Solofoniaina AE, Jeanmaire EM, 1529 Ravololomanana L, Razafimanantsoa LT, Rakotojoelinandrasana T, et al. Rift Valley 1530 fever during rainy seasons, Madagascar, 2008 and 2009. Emerg Infect Dis. 1531 2010;16(6):963-970. doi: 10.3201/eid1606.091266. 1532 1533 93. Faye O, Ba H, Ba Y, Freire CC, Faye O, Ndiaye O, et al. Reemergence of Rift 1534 Valley fever, Mauritania, 2010. Emerg Infect Dis. 2014;20(2):300-303. Epub 2014/01/23. 1535 doi: 10.3201/eid2002.130996. 1536 1537 94. Sow A, Fave O, Ba Y, Diallo D, Fall G, Fave O, et al. Widespread Rift Valley fever emergence in Senegal in 2013-2014. Open Forum Infect Dis. 2016;3(3):ofw149. Epub 1538 1539 2016/10/06. doi: 10.1093/ofid/ofw149. 1540 1541 95. Sow A, Faye O, Ba Y, Ba H, Diallo D, Faye O, et al. Rift Valley fever outbreak, 1542 southern Mauritania, 2012. Emerg Infect Dis. 2014;20(2):296-299. Epub 2014/01/23. 1543 doi: 10.3201/eid2002.131000. 1544 1545 96. Lagare A, Fall G, Ibrahim A, Ousmane S, Sadio B, Abdoulaye M, et al. First 1546 occurrence of Rift Valley fever outbreak in Niger, 2016. Vet Med Sci. 2019;5(1):70-78. 1547 Epub 2018/11/10. doi: 10.1002/vms3.135. 1548 1549 97. Grobbelaar AA, Wever J, Leman PA, Kemp A, Paweska JT, Swanepoel R. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis. 2011;17(12):2270-1550 1551 2276. Epub 2011/12/17. doi: 10.3201/eid1712.111035. 1552 1553 98. van Schalkwyk A, Gwala S, Schuck KN, Quan M, Davis AS, Romito M, et al. Retrospective phylogenetic analyses of formalin-fixed paraffin-embedded samples from 1554 1555 the 2011 Rift Valley fever outbreak in South Africa, through sequencing of targeted regions. J Virol Methods. 2020;287:114003. Epub 2020/11/10. doi: 1556 1557 10.1016/j.jviromet.2020.114003. 1558 1559 99. van Schalkwyk A, Romito M. Genomic characterization of Rift Valley fever virus, 1560 South Africa, 2018. Emerg Infect Dis. 2019;25(10):1979-1981. Epub 2019/09/21. doi: 1561 10.3201/eid2510.181748. 1562 1563 100. Liu W, Sun FJ, Tong YG, Zhang SQ, Cao WC. Rift Valley fever virus imported into China from Angola. Lancet Infect Dis. 2016;16(11):1226. Epub 2016/10/30. doi: 1564 1565 10.1016/s1473-3099(16)30401-7.
- 1566

1567 1568 1569 1570	101. Grobbelaar AA, Weyer J, Leman P, Kemp A, Paweska JT. Phylogeny of Rift Valley fever virus isolates recovered from humans during 2008-2011 disease outbreaks in South Africa. International Journal of Infectious Diseases. 2014;21:224-224. doi: 10.1016/j.ijid.2014.03.887.
1571 1572 1573 1574	102. Bett B, Said MY, Sang R, Bukachi S, Wanyoike S, Kifugo SC, et al. Effects of flood irrigation on the risk of selected zoonotic pathogens in an arid and semi-arid area in the eastern Kenya. PLoS One. 2017;12(5). doi: 10.1371/journal.pone.0172626.
1575 1576 1577 1578 1579	103. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, Morrill J, et al. Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a village cohort study. PLoS Negl Trop Dis. 2011;5(8):e1265. doi: 10.1371/journal.pntd.0001265.
1580 1581 1582 1583 1584	104. Arishi H, Ageel A, Rahman MA, Al Hazmi A, Arishi AR, Ayoola B, et al. Update: Outbreak of Rift Valley fever - Saudi Arabia, August-November 2000 (Reprinted from MMWR, vol 49, pg 982-986, 2000). Journal of the American Medical Association. 2000;284(23):2989-2990.
1585 1586 1587	105. Rift Valley fever, Saudi Arabia, August-October 2000. Wkly Epidemiol Rec. 2000;75(46):370-371. Epub 2001/01/06.
1588 1589 1590	106. Outbreak of Rift Valley fever, Yemen, August-October 2000. Wkly Epidemiol Rec. 2000;75(48):392-395. Epub 2001/01/06.
1591 1592 1593 1594 1595 1596	107. Hanafi HA, Fryauff DJ, Saad MD, Soliman AK, Mohareb EW, Medhat I, et al. Virus isolations and high population density implicate <i>Culex antennatus</i> (Becker) (Diptera: Culicidae) as a vector of Rift Valley fever virus during an outbreak in the Nile Delta of Egypt. Acta Trop. 2011;119(2-3):119-124. Epub 2011/05/17. doi: 10.1016/j.actatropica.2011.04.018.
1597 1598 1599 1600	108. Faye O, Diallo M, Diop D, Bezeid OE, Bâ H, Niang M, et al. Rift Valley fever outbreak with East-Central African virus lineage in Mauritania, 2003. Emerg Infect Dis. 2007;13(7):1016-1023. Epub 2008/01/25. doi: 10.3201/eid1307.061487.
1601 1602 1603 1604	109. Sindato C, Karimuribo ED, Pfeiffer DU, Mboera LE, Kivaria F, Dautu G, et al. Spatial and temporal pattern of Rift Valley fever outbreaks in Tanzania; 1930 to 2007. PLoS One. 2014;9(2):e88897. Epub 2014/03/04. doi: 10.1371/journal.pone.0088897.
1605	

1606 1607 1608	110. El Mamy AB, Baba MO, Barry Y, Isselmou K, Dia ML, El Kory MO, et al. Unexpected Rift Valley fever outbreak, northern Mauritania. Emerg Infect Dis. 2011;17(10):1894-1896. Epub 2011/10/18. doi: 10.3201/eid1710.110397.
1609 1610 1611 1612	111. El Mamy AB, Kane Y, El Arbi AS, Barry Y, Bernard C, Lancelot R, et al. L'épidémie de la fièvre de la Vallé du Rift en 2012 en Mauritanie. Revue Africaine de Santé et Productions Animales. 2014;12(3-4):169-173.
1613 1614 1615 1616 1617	112. Shoemaker T, Balinandi S, Nyakarahuka L, Ojwang J, Tumusiime A, Mulei S, et al. First laboratory confirmation of an outbreak of Rift Valley fever virus in 50 Years in Kabale District, southwestern Uganda. American Journal of Tropical Medicine and Hygiene. 2017;95(5):437-437.
1618 1619 1620 1621 1622	113. Hassan A, Muturi M, Mwatondo A, Omolo J, Bett B, Gikundi S, et al. Epidemiological investigation of a Rift Valley fever outbreak in humans and livestock in Kenya, 2018. Am J Trop Med Hyg. 2020;103(4):1649-1655. Epub 2020/08/05. doi: 10.4269/ajtmh.20-0387.
1623 1624 1625 1626	114. Youssouf H, Subiros M, Dennetiere G, Collet L, Dommergues L, Pauvert A, et al. Rift Valley fever outbreak, Mayotte, France, 2018-2019. Emerg Infect Dis. 2020;26(4):769-772. Epub 2020/03/19. doi: 10.3201/eid2604.191147.
1627 1628 1629 1630	115. van Vuren PJ, Kgaladi J, Patharoo V, Ohaebosim P, Msimang V, Nyokong B, et al. Human cases of Rift Valley fever in South Africa, 2018. Vector-Borne and Zoonotic Diseases. 2018;18(12):713-715. doi: 10.1089/vbz.2018.2357.
1631 1632 1633 1634	116. Youssef HM, Ghoneim MA, al. e. Recent trends for diagnosis of Rift Valley fever in animals and mosquitoes in Egypt with special reference to the carrier. Global Veterinaria. 2008;2(1).
1635 1636 1637 1638	117. Jeffries CL, Tantely LM, Raharimalala FN, Hurn E, Boyer S, Walker T. Diverse novel resident <i>Wolbachia</i> strains in Culicine mosquitoes from Madagascar. Scientific Reports. 2018;8. doi: 10.1038/s41598-018-35658-z.
1639 1640 1641 1642	118. Ndiaye EH, Diallo D, Fall G, Ba Y, Faye O, Dia I, et al. Arboviruses isolated from the Barkedji mosquito-based surveillance system, 2012-2013. BMC Infect Dis. 2018;18(1):642. Epub 2018/12/14. doi: 10.1186/s12879-018-3538-2.
1643	

1644 1645 1646	119. Abdelgadir DM, Bashab HMM, Mohamed RAE, Abuelmaali SA. Risk factor analysis for outbreak of Rift Valley fever in Khartoum State of Sudan. Journal of Entomological Science. 2010;45(3):239-251. doi: 10.18474/0749-8004-45.3.239.
1647 1648 1649 1650	120. Mbanzulu KM, Mboera LEG, Luzolo FK, Wumba R, Misinzo G, Kimera SI. Mosquito-borne viral diseases in the Democratic Republic of the Congo: a review. Parasit Vectors. 2020;13(1):103. Epub 2020/02/28. doi: 10.1186/s13071-020-3985-7.
1651 1652 1653 1654 1655	121. Mohamed RAE, Mohamed N, Aleanizy FS, Alqahtani FY, Al Khalaf A, Al-Keridis LA. Investigation of hemorrhagic fever viruses inside wild populations of ticks: One of the pioneer studies in Saudi Arabia. Asian Pacific Journal of Tropical Disease. 2017;7:299-303.
1656 1657 1658 1659 1660	122. Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg. 2010;83(2 Suppl):22-27. doi: 10.4269/ajtmh.2010.09-0318.
1661 1662 1663 1664 1665	123. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ, Traylor Z, et al. Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya. PLoS Negl Trop Dis. 2015;9(3):e0003548. Epub 2015/03/13. doi: 10.1371/journal.pntd.0003548.
1666 1667 1668 1669	124. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO, Mutonga D, et al. Risk factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg. 2010;83(2 Suppl):14-21. doi: 10.4269/ajtmh.2010.09-0293.
1670 1671 1672 1673	125. Seufi AM, Galal FH. Role of <i>Culex</i> and <i>Anopheles</i> mosquito species as potential vectors of Rift Valley fever virus in Sudan outbreak, 2007. BMC Infect Dis. 2010;10:65. Epub 2010/03/13. doi: 10.1186/1471-2334-10-65.
1674 1675 1676 1677 1678	126. Oyas H, Holmstrom L, Kemunto NP, Muturi M, Mwatondo A, Osoro E, et al. Enhanced surveillance for Rift Valley fever in livestock during El Niño rains and threat of RVF outbreak, Kenya, 2015-2016. PLoS Negl Trop Dis. 2018;12(4):e0006353. Epub 2018/04/27. doi: 10.1371/journal.pntd.0006353.
1679 1680 1681 1682	127. Bashir RSE, Hassan OA. A One Health perspective to identify environmental factors that affect Rift Valley fever transmission in Gezira state, Central Sudan. Tropical Medicine and Health. 2019;47(1). doi: 10.1186/s41182-019-0178-1.
1683	

1684 1685 1686	128. van Vuren PJ, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J, Tiemessen CT, et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease. Virology Journal. 2015;12. doi: 10.1186/s12985-015-0392-3.
1687 1688 1689	129. Outbreak news. Rift Valley fever, Kenya. Wkly Epidemiol Rec. 2007;82(3):17-18. Epub 2007/01/24.
1690 1691 1692 1693	130. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003;37(8):1084-1092. doi: 10.1086/378747.
1694 1695 1696 1697 1698	131. Njenga MK, Paweska J, Wanjala R, Rao CY, Weiner M, Omballa V, et al. Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases. J Clin Microbiol. 2009;47(4):1166-1171. Epub 2009/01/28. doi: 10.1128/jcm.01905-08.
1699 1700 1701 1702 1703	132. Bett B, Lindahl J, Sang R, Wainaina M, Kairu-Wanyoike S, Bukachi S, et al. Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya. Epidemiology and Infection. 2019;147. doi: 10.1017/S0950268818003242.
1704 1705 1706 1707 1708	133. Nicolas G, Chevalier V, Tantely LM, Fontenille D, Durand B. A spatially explicit metapopulation model and cattle trade analysis suggests key determinants for the recurrent circulation of Rift Valley fever virus in a pilot area of Madagascar highlands. PLoS Negl Trop Dis. 2014;8(12):e3346. doi: 10.1371/journal.pntd.0003346.
1709 1710 1711 1712 1713	134. Metras R, Cavalerie L, Dommergues L, Merot P, Edmunds WJ, Keeling MJ, et al. The epidemiology of Rift Valley fever in Mayotte: insights and perspectives from 11 years of data. PloS Neglected Tropical Diseases. 2016;10(6). doi: 10.1371/journal.pntd.0004783.
1714 1715 1716	135. Alhaj M. Surveillance study on Rift Valley fever in Jazan region, Saudi Arabia. Int J Adv Sci Tech Res. 2015;5(4):1-13.
1717 1718 1719 1720 1721	136. Ngoshe YB, Avenant A, Rostal MK, Karesh WB, Paweska JT, Bagge W, et al. Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South Africa four years after a large outbreak. Scientific Reports. 2020;10(1). doi: 10.1038/s41598-020-62453-6.
1722	

1723	137. Moiane B, Mapaco L, Thompson P, Berg M, Albihn A, Fafetine J. High
1724 1725	seroprevalence of Rift Valley fever phlebovirus in domestic ruminants and African Buffaloes in Mozambique shows need for intensified surveillance. Infect Ecol Epidemiol.
1726	2017;7(1):1416248. Epub 2018/01/13. doi: 10.1080/20008686.2017.1416248.
1727	
1728	138. Caron A, Cornelis D, Foggin C, Hofmeyr M, de Garine-Wichatitsky M. African
1729	Buffalo movement and zoonotic disease risk across transfrontier conservation areas,
1730 1731	Southern Africa. Emerg Infect Dis. 2016;22(2):277-280. Epub 2016/01/27. doi: 10.3201/eid2202.140864.
1732	
1732	139. Byomi AM, Samaha HA, Zidan SA, Hadad GA. Some associated risk factors with
1734	the occurence of Rift Valley fever in animals and man in certain localities of Nile delta,
1735	Egypt. Assiut Veterinary Medical Journal. 2015;61:10-17.
1736	440 Mahamad ANA Ashahi ANA Ashan All Ahd El Dahim III El Ohami AO. Zafar T
1737 1738	140. Mohamed AM, Ashshi AM, Asghar AH, Abd El-Rahim IH, El-Shemi AG, Zafar T. Seroepidemiological survey on Rift Valley fever among small ruminants and their close
1739	human contacts in Makkah, Saudi Arabia, in 2011. Rev Sci Tech. 2014;33(3):903-915.
1740	doi: 10.20506/rst.33.3.2328.
1741	
1742 1743	141. Wensman JJ, Lindahl J, Wachtmeister N, Torsson E, Gwakisa P, Kasanga C, et al. A study of Rift Valley fever virus in Morogoro and Arusha regions of Tanzania -
1744	serology and farmers' perceptions. Infect Ecol Epidemiol. 2015;5:30025. doi:
1745	10.3402/iee.v5.30025.
1746	
1747	142. Elfadil AA, Hasab-Allah KA, Dafa-Allah OM. Factors associated with Rift Valley
1748	fever in south-west Saudi Arabia. Rev Sci Tech. 2006;25(3):1137-1145.
1749 1750	143. Mdlulwa Z, Ngwane CB. Evaluating the impact of 2010 Rift Valley fever outbreaks
1750	on sheep numbers in three provinces of South Africa. African Journal of Agricultural
1752	Research. 2017;12(11):979–986.
1753	
1754	144. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, et al.
1755 1756	Rift Valley fever virus infections in Egyptian cattle and their prevention. Transbound Emerg Dis. 2017;64(6):2049-2058. Epub 2017/01/25. doi: 10.1111/tbed.12616.
1757	
1757	145. Abbas B, Yousif MA, M. NH. Animal health constraints to livestock exports from
1759	the Horn of Africa. Rev Sci Tech. 2014;33(3): 711-721.
1760	

72

1761 146. Mohamed AM, Ghazi H, Ashshi AM, Faidah HS, Clinical EIA. Serological survey of
1762 Rift Valley fever among sacrifice animals in holy Mecca during pilgrimage season. . Int J
1763 Trop Med. 2011;6(4):85–89.

1764

1765 147. Tong C, Javelle E, Grard G, Dia A, Lacrosse C, Fourié T, et al. Tracking Rift Valley
1766 fever: From Mali to Europe and other countries, 2016. Euro Surveill. 2019;24(8). Epub
1767 2019/02/28. doi: 10.2807/1560-7917.es.2019.24.8.1800213.

1768

- 1769 148. Liu B, Ma J, Jiao Z, Gao X, Xiao J, Wang H. Risk assessment for the Rift Valley 1770 fever occurrence in China: Special concern in south-west border areas. Transbound
- 1771 Emerg Dis. 2020. Epub 2020/06/23. doi: 10.1111/tbed.13695.

1772

- 1773 149. Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: Important considerations for
- 1774 risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2). doi:
- 1775 **10.3390/tropicalmed5020089**.

1776

- 1777 150. O'Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et
- al. Serosurveillance of viral pathogens circulating in West Africa. Virol J.
- 1779 2016;13(1):163. Epub 2016/10/08. doi: 10.1186/s12985-016-0621-4.

1780

- 1781 151. LaBeaud AD, Ochiai Y, Peters CJ, Muchiri EM, King CH. Spectrum of Rift Valley
- 1782 fever virus transmission in Kenya: Insights from three distinct regions. American Journal
- 1783 of Tropical Medicine and Hygiene. 2007;76(5):795-800. doi:
- 1784 10.4269/ajtmh.2007.76.795.

1785

1786 152. Grossi-Soyster EN, Banda T, Teng CY, Muchiri EM, Mungai PL, Mutuku FM, et al.
1787 Rift Valley fever seroprevalence in coastal Kenya. Am J Trop Med Hyg. 2017;97(1):115120. Epub 2017/07/19. doi: 10.4269/ajtmh.17-0104.

1789

1790 153. Cook EAJ, Grossi-Soyster EN, de Glanville WA, Thomas LF, Kariuki S, Bronsvoort
1791 BMD, et al. The sero-epidemiology of Rift Valley fever in people in the Lake Victoria
1792 Basin of western Kenya. Plos Neglected Tropical Diseases. 2017;11(7). doi:
1703 12014 January 1 antid 0005721

1793 10.1371/journal.pntd.0005731.

1794

1795 154. Gray GC, Anderson BD, LaBeaud AD, Heraud JM, Fevre EM, Andriamandimby 1796 SF, et al. Seroepidemiological study of interepidemic Rift Valley fever virus infection 1797 among persons with intense ruminant exposure in Madagascar and Kenya. Am J Trop

1798 Med Hyg. 2015;93(6):1364-1370. doi: 10.4269/ajtmh.15-0383.

73

1800 155. LaBeaud AD, Bashir F, King CH. Measuring the burden of arboviral diseases: the 1801 spectrum of morbidity and mortality from four prevalent infections. Population Health 1802 Metrics. 2011;9. doi: 10.1186/1478-7954-9-1. 1803 1804 156. Muiruri S, Kabiru EW, Muchiri EM, Hussein H, Kagondu F, LaBeaud AD, et al. 1805 Cross-sectional survey of Rift Valley fever virus exposure in Bodhei village located in a 1806 transitional coastal forest habitat in Lamu County, Kenya. Am J Trop Med Hyg. 1807 2015;92(2):394-400. Epub 2014/12/24. doi: 10.4269/ajtmh.14-0440. 1808 1809 157. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, et al. A systematic review of Rift Valley fever epidemiology 1931-2014. Infect Ecol Epidemiol. 1810 1811 2015;5:28024. Epub 2015/08/04. doi: 10.3402/iee.v5.28024. 1812 1813 158. Jori F, Godfroid J, Michel AL, Potts AD, Jaumally MR, Sauzier J, et al. An 1814 assessment of zoonotic and production limiting pathogens in rusa deer (Cervus 1815 *timorensis rusa*) from Mauritius. Transbound Emerg Dis. 2014;61 Suppl 1:31-42. doi: 1816 10.1111/tbed.12206. 1817 1818 159. Elfving K, Shakely D, Andersson M, Baltzell K, Ali AS, Bachelard M, et al. Acute 1819 uncomplicated febrile illness in children aged 2-59 months in Zanzibar - aetiologies, 1820 antibiotic treatment and outcome. PLoS One. 2016;11(1):e0146054. Epub 2016/01/29. 1821 doi: 10.1371/journal.pone.0146054. 1822 1823 160. Nicolas G, Durand B, Duboz R, Rakotondravao R, Chevalier V. Description and 1824 analysis of the cattle trade network in the Madagascar highlands: potential role in the 1825 diffusion of Rift Valley fever virus. Acta Trop. 2013;126(1):19-27. doi: 1826 10.1016/j.actatropica.2012.12.013. 1827 1828 161. Abdo-Salem S, Tran A, Grosbois V, Gerbier G, Al-Qadasi M, Saeed K, et al. Can 1829 environmental and socioeconomic factors explain the recent emergence of Rift Valley 1830 fever in Yemen, 2000-2001? Vector Borne Zoonotic Dis. 2011;11(6):773-779. Epub 1831 2011/02/03. doi: 10.1089/vbz.2010.0084. 1832 1833 162. Xiao Y, Beier JC, Cantrell RS, Cosner C, DeAngelis DL, Ruan S. Modelling the 1834 effects of seasonality and socioeconomic impact on the transmission of Rift Valley fever 1835 virus. PLoS Negl Trop Dis. 2015;9(1):e3388. Epub 2015/01/09. doi: 1836 10.1371/journal.pntd.0003388.

74

1838 1839 1840	163. Apolloni A, Nicolas G, Coste C, El Mamy AB, Yahya B, El Arbi AS, et al. Towards the description of livestock mobility in Sahelian Africa: Some results from a survey in Mauritania. PLoS One. 2018;13(1). doi: 10.1371/journal.pone.0191565.
1841 1842 1843 1844	164. Bergren NA, Borland EM, Hartman DA, Kading RC. Laboratory demonstration of the vertical transmission of Rift Valley fever virus by <i>Culex tarsalis</i> mosquitoes. PLoS Negl Trop Dis. 2021;15(3):e0009273. doi: 10.1371/journal.pntd.0009273.
1845 1846 1847 1848	165. Antonis AF, Kortekaas J, Kant J, Vloet RP, Vogel-Brink A, Stockhofe N, et al. Vertical transmission of Rift Valley fever virus without detectable maternal viremia. Vector Borne Zoonotic Dis. 2013;13(8):601-606. doi: 10.1089/vbz.2012.1160.
1849 1850 1851 1852	166. Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a pregnant Sudanese woman. J Med Virol. 2008;80(5):929. Epub 2008/03/25. doi: 10.1002/jmv.21132.
1853 1854 1855 1856	167. Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever in a newborn. Ann Trop Paediatr. 2006;26(3):251-253. doi: 10.1179/146532806X120363.
1857 1858 1859 1860 1861	168. Baudin M, Jumaa AM, Jomma HJE, Karsany MS, Bucht G, Näslund J, et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob Health. 2016;4(11):e864-e871. Epub 2016/10/22. doi: 10.1016/s2214-109x(16)30176-0.
1862 1863 1864 1865	169. Pienaar NJ, Thompson PN. Temporal and spatial history of Rift Valley fever in South Africa: 1950 to 2011. Onderstepoort J Vet Res. 2013;80(1):384. Epub 2013/05/31. doi: 10.4102/ojvr.v80i1.384.
1866 1867 1868 1869 1870 1871	170. Ndengu M, Matope G, Tivapasi M, Pfukenyi DM, Cetre-Sossah C, De Garine- Wichatitsky M. Seroprevalence and associated risk factors of Rift Valley fever in cattle and selected wildlife species at the livestock/wildlife interface areas of Gonarezhou National Park, Zimbabwe. Onderstepoort J Vet Res. 2020;87(1):e1-e7. Epub 2020/05/07. doi: 10.4102/ojvr.v87i1.1731.
1872 1873 1874 1875 1876	171. Nyakarahuka L, de St Maurice A, Purpura L, Ervin E, Balinandi S, Tumusiime A, et al. Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale district in Southwestern Uganda, 2016. PLoS Negl Trop Dis. 2018;12(5):e0006412. Epub 2018/05/04. doi: 10.1371/journal.pntd.0006412.

1878 1879	172. FAO. Rift Valley fever vaccine development, progress and constraints. Proceedings of the GF-TADs meeting, January 2011. Rome, Italy: 2011.
1880 1881 1882 1883	173. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol. 2012;2(3):315-323. Epub 2012/04/03. doi: 10.1016/j.coviro.2012.02.017.
1884 1885 1886 1887 1888	174. Shoemaker TR, Nyakarahuka L, Balinandi S, Ojwang J, Tumusiime A, Mulei S, et al. First laboratory-confirmed outbreak of human and animal Rift Valley fever virus in Uganda in 48 years. Am J Trop Med Hyg. 2019;100(3):659-671. Epub 2019/01/25. doi: 10.4269/ajtmh.18-0732.
1889 1890 1891 1892	175. Archer BN, Weyer J, Paweska J, Nkosi D, Leman P, Tint KS, et al. Outbreak of Rift Valley fever affecting veterinarians and farmers in South Africa, 2008. S Afr Med J. 2011;101(4):263-266. Epub 2011/07/27. doi: 10.7196/samj.4544.
1893 1894 1895 1896	176. Tambo E, Olalubi OA, Sacko M. Rift Valley fever epidemic in Niger near border with Mali. Lancet Infectious Diseases. 2016;16(12):1319-1320. doi: 10.1016/S1473-3099(16)30477-7.
1897 1898 1899	177. Davies FG. Risk of a Rift Valley fever epidemic at the Haj in Mecca, Saudi Arabia. Rev Sci Tech. 2006;25(1):137-147. doi: 10.20506/rst.25.1.1648.
1900 1901 1902 1903 1904	178. Krystosik A, Njoroge G, Odhiambo L, Forsyth JE, Mutuku F, LaBeaud AD. Solid wastes provide breeding sites, burrows, and food for biological disease vectors, and urban zoonotic reservoirs: A call to action for solutions-based research. Front Public Health. 2019;7:405. doi: 10.3389/fpubh.2019.00405.
1905 1906 1907	179. Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardiere A. Hajj-associated infections. Medecine et Maladies Infectieuses. 2016.
1908 1909 1910 1911	180. Cecilia H, Métras R, Fall AG, Lo MM, Lancelot R, Ezanno P. It's risky to wander in September: Modelling the epidemic potential of Rift Valley fever in a Sahelian setting. Epidemics. 2020;33:100409. Epub 2020/11/03. doi: 10.1016/j.epidem.2020.100409.
1912 1913 1914	181. Obiero JPO, Onyando JO. Climate. Chapter 5 <i>in</i> Developments in Earth Surface Processes. 16 2013. p. 39-50.

76

1916 1917 1918 1919	182. Alhaji NB, Aminu J, Lawan MK, Babalobi OO, Ghali-Mohammed I, Odetokun IA. Seropositivity and associated intrinsic and extrinsic factors for Rift Valley fever virus occurrence in pastoral herds of Nigeria: a cross sectional survey. BMC Vet Res. 2020;16(1):243. Epub 2020/07/16. doi: 10.1186/s12917-020-02455-8.
1920 1921 1922 1923 1924	183. Durand B, Lo Modou M, Tran A, Ba A, Sow F, Belkhiria J, et al. Rift Valley fever in northern Senegal: A modelling approach to analyse the processes underlying virus circulation recurrence. Plos Neglected Tropical Diseases. 2020;14(6). doi: 10.1371/journal.pntd.0008009.
1925 1926 1927 1928 1929	184. Kakani S, LaBeaud AD, King CH. Planning for Rift Valley fever virus: use of geographical information systems to estimate the human health threat of white-tailed deer ( <i>Odocoileus virginianus</i> )-related transmission. Geospat Health. 2010;5(1):33-43. doi: 10.4081/gh.2010.185.
1930 1931 1932 1933	185. Wilson WC, Kim IJ, Trujillo JD, Sunwoo SY, Noronha LE, Urbaniak K, et al. Susceptibility of white-tailed deer to Rift Valley fever virus. Emerg Infect Dis. 2018;24(9):1717-1719. Epub 2018/08/21. doi: 10.3201/eid2409.180265.
1934 1935 1936 1937	186. Bron GM, Strimbu K, Cecilia H, Lerch A, Moore SM, Tran Q, et al. Over 100 Years of Rift Valley fever: A patchwork of data on pathogen spread and spillover. Pathogens. 2021;10(6). doi: 10.3390/pathogens10060708.
1938 1939 1940 1941 1942	187. Schwarz NG, Girmann M, Randriamampionona N, Bialonski A, Maus D, Krefis AC, et al. Seroprevalence of antibodies against chikungunya, dengue, and Rift Valley fever viruses after febrile illness outbreak, Madagascar. Emerg Infect Dis. 2012;18(11):1780- 1786. doi: 10.3201/eid1811.111036.
1943 1944 1945 1946	188. Al-Qabati AG, Al-Afaleq AI. Cross-sectional, longitudinal and prospective epidemiological studies of Rift Valley fever in Al-Hasa Oasis, Saudi Arabia. Journal of Animal and Veterinary Advances. 2010;9(2):258-265.
1947 1948 1949 1950	189. Grossi-Soyster EN, Lee J, King CH, LaBeaud AD. The influence of raw milk exposures on Rift Valley fever virus transmission. PLoS Negl Trop Dis. 2019;13(3):e0007258. doi: 10.1371/journal.pntd.0007258.
1951 1952 1953 1954	190. Cook EAJ, de Glanville WA, Thomas LF, Kariuki S, Bronsvoort B, Fevre EM. Working conditions and public health risks in slaughterhouses in western Kenya. BMC Public Health. 2017;17. doi: 10.1186/s12889-016-3923-y.
10	

1956 1957 1958 1959	191. Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, et al. Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLoS One. 2017;12(12):e0189250. Epub 2017/12/22. doi: 10.1371/journal.pone.0189250.
1960 1961 1962 1963	192. WHO. Factors that contributed to undetected spread of the Ebola virus and impeded rapid containment. Geneva, Switzerland: World Health Organization; 2015 [cited 2021 9/7/2021].
1964 1965 1966 1967 1968	193. de St Maurice A, Nyakarahuka L, Purpura L, Ervin E, Tumusiime A, Balinandi S, et al. Notes from the field: Rift Valley fever response - Kabale District, Uganda, March 2016. MMWR Morb Mortal Wkly Rep. 2016;65(43):1200-1201. Epub 2016/11/05. doi: 10.15585/mmwr.mm6543a5.
1969 1970 1971 1972 1973	194. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowder GD, National Center for Foreign Animal Zoonotic Disease Defense Advisory Group on Rift Valley Fever. Potential effects of Rift Valley fever in the United States. Emerg Infect Dis. 2011;17(8):e1. doi: 10.3201/eid1708.101088.
1974 1975 1976 1977	195. Brugere-Picoux J, Chomel B. Importation of tropical diseases to Europe via animals and animal products: risks and pathways. Bulletin de L Academie Nationale de Medecine. 2009;193(8):1805-1819. doi: 10.1016/S0001-4079(19)32415-X.
1978 1979 1980 1981 1982	196. Cito F, Narcisi V, Danzetta ML, Iannetti S, Sabatino DD, Bruno R, et al. Analysis of surveillance systems in place in European Mediterranean countries for West Nile virus (WNV) and Rift Valley fever (RVF). Transbound Emerg Dis. 2013;60 Suppl 2:40-44. Epub 2014/03/05. doi: 10.1111/tbed.12124.
1983 1984 1985 1986	197. Nielsen SS, Alvarez J, Bicout DJ, Calistri P, Depner K, Drewe JA, et al. Rift Valley fever - epidemiological update and risk of introduction into Europe. EFSAJ. 2020;18(3):e06041. Epub 2020/10/07. doi: 10.2903/j.efsa.2020.6041.
1987 1988 1989 1990	198. Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus introduction and establishment in the United States and European Union. Emerg Microbes Infect. 2013;2(12):e81. Epub 2013/12/01. doi: 10.1038/emi.2013.81.
1991 1992 1993 1994	199. Zeller H, Marrama L, Sudre B, Van Bortel W, Warns-Petit E. Mosquito-borne disease surveillance by the European Centre for Disease Prevention and Control. Clin Microbiol Infect. 2013;19(8):693-698. Epub 2013/04/24. doi: 10.1111/1469-0691.12230.
1995	

78

1996 1997 1998	200. Lagerqvist N, Moiane B, Mapaco L, Fafetine J, Vene S, Falk KI. Antibodies against Rift Valley fever virus in cattle, Mozambique. Emerg Infect Dis. 2013;19(7):1177-1179. Epub 2013/06/15. doi: 10.3201/eid1907.130332.
1999 2000 2001 2002 2003	201. Abakar MF, Nare NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J. Seroprevalence of Rift Valley fever, Q Fever, and brucellosis in ruminants on the southeastern shore of Lake Chad. Vector-Borne and Zoonotic Diseases. 2014;14(10):757-762. doi: 10.1089/vbz.2014.1585.
2004 2005 2006 2007	202. Consultative Group for RVF Decision Support. Decision-support tool for prevention and control of Rift Valley fever epizootics in the Greater Horn of Africa. Am J Trop Med Hyg. 2010;83(2 Suppl):75-85. doi: 10.4269/ajtmh.2010.83s2a03.
2008 2009 2010 2011 2012	203. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al. High dengue burden and circulation of 4 virus serotypes among children with undifferentiated fever, Kenya, 2014-2017. Emerg Infect Dis. 2020;26(11):2638-2650. doi: 10.3201/eid2611.200960.
2013 2014 2015 2016	204. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al. Unrecognized dengue virus infections in children, western Kenya, 2014-2015. Emerg Infect Dis. 2017;23(11):1915-1917. doi: 10.3201/eid2311.170807.
2017 2018 2019 2020	205. Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster EN, et al. Acute flavivirus and alphavirus infections among children in two different areas of Kenya, 2015. Am J Trop Med Hyg. 2019;100(1):170-173. doi: 10.4269/ajtmh.18-0297.
2021 2022 2023 2024	206. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg. 2012;86(1):171-177. doi: 10.4269/ajtmh.2012.11-0393.
2025 2026 2027 2028 2029	207. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61. Epub 2010/12/29. doi: 10.1051/vetres/2010033.
2030 2031 2032 2033	208. Fakour S, Naserabadi S, Ahmadi E. The first positive serological study on Rift Valley fever in ruminants of Iran. J Vector Borne Dis. 2017;54(4):348-352. Epub 2018/02/21. doi: 10.4103/0972-9062.225840.
2024	

- 2035 209. Amato L, Dente MG, Calistri P, Declich S. Integrated early warning surveillance:
- 2036 Achilles' Heel of One Health? Microorganisms. 2020;8(1). doi:
- 2037 10.3390/microorganisms8010084.
- 2038
- 2039 210. Hassan OA, Ahlm C, Evander M. A need for One Health approach lessons 2040 learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan. Infect Ecol
- learned from outbreaks of Rift Valley fever in Saudi Arabia and Sud
   Epidemiol. 2014;4. Epub 2014/02/08. doi: 10.3402/iee.v4.20710.
- 2042

# 2043 Supporting Information

- 2044 **Text**:
- 2045 **S1 Text.** Information sources and detailed scripts used in running the searches on the
- 2046 online databases
- 2047 *Figures:*
- 2048 **S1 Figure.** Forest Plot for meta-analysis of the impact of butchering on odds of RVFV
- 2049 exposure
- 2050 S2 Figure. Forest Plot for meta-analysis of the impact of sheltering animals on odds of
- 2051 RVFV exposure
- 2052 S3 Figure. Forest Plot for meta-analysis of the impact of milking animals on odds of
- 2053 RVFV exposure
- 2054 **Tables:**
- 2055 S1 Table. PRISMA checklist
- 2056 **S2 Table.** Listing of included studies with full citations
- 2057 **S3 Table.** Listing of excluded studies with full citations
- 2058 **S4 Table.** Listing by year of countries experiencing human or animal exposure to RVFV
- 2059 during 1999-2021

- **S5 Table.** Listing of acute human cases reported during 1999-2021. Outbreaks are
- indicated by year, country, region, and geographic location, with estimated population
- 2062 size, incidence, and case fatality rates
- **S6 Table.** Studies of RVFV lineage distribution based on genetic sequence analysis
- **S7 Table.** 1999-2021 studies of local insect vector presence and RVFV infection
- **S8 Table.** Studies assessing human risk factors related to animal exposures and severe
- 2066 RVFV disease
- **S9 Table.** Studies of the effects of socioeconomic status on human RVFV exposure risk
- **S10 Table.** Studies of the effects of occupation on human RVFV exposure risk
- **S11 Table.** Livestock factors related to animal RVFV exposure risk
- **S12 Table.** Wildlife anti-RVFV seroprevalence reported in included studies
- **S13 Table.** Local and national RVF surveillance systems reported in included studies